{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:59:49Z","timestamp":1793642389097,"version":"4.5.1"},"reference-count":404,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T00:00:00Z","timestamp":1423180800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12916-014-0259-2","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T12:03:50Z","timestamp":1423137830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses"],"prefix":"10.1186","volume":"13","author":[{"given":"Gerwyn","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Walder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,6]]},"reference":[{"key":"259_CR1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1741-7015-11-64","volume":"11","author":"G Morris","year":"2013","unstructured":"Morris G, Anderson G, Galecki P, Berk M, Maes M. A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) and sickness behavior. BMC Med. 2013;11:64.","journal-title":"BMC Med"},{"key":"259_CR2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/rheumatology\/keq454","volume":"50","author":"K Norheim","year":"2011","unstructured":"Norheim K, Jonsson G, Omdal R. Biological mechanisms of chronic fatigue. Rheumatology. 2011;50:1009\u201318.","journal-title":"Rheumatology"},{"key":"259_CR3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jc.2013-3092","volume":"99","author":"I Jialal","year":"2014","unstructured":"Jialal I, Kaur H, Devaraj S. Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. J Clin Endocrinol Metab. 2014;99:39\u201348.","journal-title":"J Clin Endocrinol Metab"},{"key":"259_CR4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12035-013-8425-7","volume":"48","author":"K Lucas","year":"2013","unstructured":"Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol. 2013;48:190\u2013204.","journal-title":"Mol Neurobiol"},{"key":"259_CR5","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1152\/japplphysiol.01499.2011","volume":"112","author":"R Fernandez-Gonzalo","year":"2012","unstructured":"Fernandez-Gonzalo R, De Paz JA, Rodriguez-Miguelez P, Cuevas MJ, Gonz\u00e1lez-Gallego J. Effects of eccentric exercise on toll-like receptor 4 signaling pathway in peripheral blood mononuclear cells. J Appl Physiol. 2012;112:2011\u20138.","journal-title":"J Appl Physiol"},{"key":"259_CR6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11011-012-9324-8","volume":"28","author":"G Morris","year":"2013","unstructured":"Morris G, Maes M. A neuro-immune model of Myalgic Encephalomyelitis\/Chronic fatigue syndrome. Metab Brain Dis. 2013;28:523\u201340.","journal-title":"Metab Brain Dis"},{"key":"259_CR7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/1570159X11666131120224653","volume":"12","author":"G Morris","year":"2014","unstructured":"Morris G, Maes M. Oxidative and nitrosative stress and immune-inflammatory pathways in patients with Myalgic Encephalomyelitis (ME)\/Chronic Fatigue Syndrome (CFS). Curr Neuropharmacol. 2014;12:168\u201385.","journal-title":"Curr Neuropharmacol"},{"key":"259_CR8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00019052-200206000-00020","volume":"15","author":"VH Perry","year":"2002","unstructured":"Perry VH, Cunningham C, Boche D. Atypical inflammation in the central nervous system in prion disease. Curr Opin Neurol. 2002;15:349\u201354.","journal-title":"Curr Opin Neurol"},{"key":"259_CR9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.bbi.2004.01.004","volume":"18","author":"VH Perry","year":"2004","unstructured":"Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun. 2004;18:407\u201313.","journal-title":"Brain Behav Immun"},{"key":"259_CR10","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.2353\/ajpath.2010.091235","volume":"176","author":"D Londo\u00f1o","year":"2010","unstructured":"Londo\u00f1o D, Cadavid D. Bacterial lipoproteins can disseminate from the periphery to inflame the brain. Am J Pathol. 2010;176:2848\u201357.","journal-title":"Am J Pathol"},{"key":"259_CR11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00401-010-0722-x","volume":"120","author":"VH Perry","year":"2010","unstructured":"Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010;120:277\u201386.","journal-title":"Acta Neuropathol"},{"key":"259_CR12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrneurol.2010.17","volume":"6","author":"VH Perry","year":"2010","unstructured":"Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6:193\u2013201.","journal-title":"Nat Rev Neurol"},{"key":"259_CR13","doi-asserted-by":"crossref","first-page":"a009381","DOI":"10.1101\/cshperspect.a009381","volume":"2","author":"RL Mosley","year":"2012","unstructured":"Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2:a009381.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"259_CR14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","volume":"73","author":"C Holmes","year":"2009","unstructured":"Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768\u201374.","journal-title":"Neurology"},{"key":"259_CR15","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.bbi.2010.05.006","volume":"24","author":"C Heesen","year":"2010","unstructured":"Heesen C, Schulz KH, Fiehler J, Von der Mark U, Otte C, Jung R, et al. Correlates of cognitive dysfunction in multiple sclerosis. Brain Behav Immun. 2010;24:1148\u201355.","journal-title":"Brain Behav Immun"},{"key":"259_CR16","first-page":"673","volume":"21","author":"H Arai","year":"2006","unstructured":"Arai H, Furuya T, Mizuno Y, Mochizuki H. Inflammation and infection in Parkinson\u2019s disease. Histol Histopathol. 2006;21:673\u20138.","journal-title":"Histol Histopathol"},{"key":"259_CR17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1741-7015-11-205","volume":"11","author":"G Morris","year":"2013","unstructured":"Morris G, Maes M. Myalgic encephalomyelitis\/chronic fatigue syndrome and encephalomyelitis disseminata\/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. 2013;11:205.","journal-title":"BMC Med"},{"key":"259_CR18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1600-0404.2010.01381.x","volume":"190","author":"AG Beiske","year":"2010","unstructured":"Beiske AG, Svensson E. Fatigue in Parkinson\u2019s disease: a short update. Acta Neurol Scand Suppl. 2010;190:78\u201381.","journal-title":"Acta Neurol Scand Suppl"},{"key":"259_CR19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1741-7015-11-200","volume":"11","author":"M Berk","year":"2013","unstructured":"Berk M, Williams L, Jacka F, O\u2019Neil A, Pasco J, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200.","journal-title":"BMC Med"},{"key":"259_CR20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1741-7015-10-66","volume":"10","author":"M Maes","year":"2012","unstructured":"Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012;10:66.","journal-title":"BMC Med"},{"key":"259_CR21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/mp.2013.155","volume":"19","author":"T Kreisel","year":"2014","unstructured":"Kreisel T, Frank M, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV, et al. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry. 2014;19:699\u2013709.","journal-title":"Mol Psychiatry"},{"key":"259_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-8-94","volume":"8","author":"J Steiner","year":"2011","unstructured":"Steiner J, Walter M, Gos T, Guillemin G, Bernstein H, Sarnyai Z, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission. J Neuroinflammation. 2011;8:1\u20139.","journal-title":"J Neuroinflammation"},{"key":"259_CR23","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.24311","volume":"59","author":"B Segal","year":"2008","unstructured":"Segal B, Thomas W, Rogers T, Leon JM, Hughes P, Patel D, et al. Prevalence, severity, and predictors of fatigue in subjects with primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 2008;59:1780\u20137.","journal-title":"Arthritis Rheum"},{"key":"259_CR24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/ijr.12.4","volume":"7","author":"GE Ahn","year":"2012","unstructured":"Ahn GE, Ramsey-Goldman R. Fatigue in systemic lupus erythematosus. Int J Clin Rheumtol. 2012;7:217\u201327.","journal-title":"Int J Clin Rheumtol"},{"key":"259_CR25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/ard.2010.144691","volume":"70","author":"S Hewlett","year":"2011","unstructured":"Hewlett S, Ambler N, Almeida C, Cliss A, Hammond A, Kitchen K, et al. Self-management of fatigue in rheumatoid arthritis: a randomised controlled trial of group cognitive-behavioural therapy. Ann Rheum Dis. 2011;70:1060\u20137.","journal-title":"Ann Rheum Dis"},{"key":"259_CR26","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","volume":"108","author":"N Sattar","year":"2003","unstructured":"Sattar N, McCarey D, Capell H, McInnes I. Explaining how a \u201chigh-grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957\u201363.","journal-title":"Circulation"},{"key":"259_CR27","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1253\/circj.CJ-09-0274","volume":"73","author":"I Ku","year":"2009","unstructured":"Ku I, Imboden J, Hsue P, Ganz P. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J. 2009;73:977\u201385.","journal-title":"Circ J"},{"key":"259_CR28","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/art.24535","volume":"60","author":"L Munoz","year":"2009","unstructured":"Munoz L, Janko C, Grossmayer G, Frey B, Voll R, Kern P, et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1733\u201342.","journal-title":"Arthritis Rheum"},{"key":"259_CR29","first-page":"676284","volume":"2010","author":"HM Lee","year":"2010","unstructured":"Lee HM, Sugino H, Nishimoto N. Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:676284.","journal-title":"J Biomed Biotechnol"},{"key":"259_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/iep.12061","volume":"95","author":"M Sisto","year":"2014","unstructured":"Sisto M, Lisi S, Ingravallo G, Lofrumento D, D\u2019Amore M, Ribatti D. Neovascularization is prominent in the chronic inflammatory lesions of Sj\u00f6gren\u2019s syndrome. Int J Exp Pathol. 2014;95:131\u20137.","journal-title":"Int J Exp Pathol"},{"key":"259_CR31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cyto.2012.12.021","volume":"61","author":"S Lisi","year":"2013","unstructured":"Lisi S, Sisto M, D\u2019Amore M, Lofrumento D, Ribatti D. Emerging avenues linking inflammation, angiogenesis and Sj\u00f6gren\u2019s syndrome. Cytokine. 2013;61:693\u2013703.","journal-title":"Cytokine"},{"key":"259_CR32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ncl.2009.09.004","volume":"28","author":"E Muscal","year":"2010","unstructured":"Muscal E, Brey R. Neurological manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010;28:61\u201373.","journal-title":"Neurol Clin"},{"key":"259_CR33","first-page":"645967","volume":"2012","author":"G Tob\u00f3n","year":"2012","unstructured":"Tob\u00f3n G, Pers J, Devauchelle-Pensec V, Youinou P. Neurological disorders in primary Sj\u00f6gren\u2019s syndrome. Autoimmune Dis. 2012;2012:645967.","journal-title":"Autoimmune Dis"},{"key":"259_CR34","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4088\/JCP.11r07425","volume":"73","author":"Z Meszaros","year":"2012","unstructured":"Meszaros Z, Perl A, Faraone S. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry. 2012;73:993\u20131001.","journal-title":"J Clin Psychiatry"},{"key":"259_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10067-011-1841-z","volume":"31","author":"C Ramos-Remus","year":"2012","unstructured":"Ramos-Remus C, Duran-Barragan S, Castillo-Ortiz J. Beyond the joints: neurological involvement in rheumatoid arthritis. Clin Rheumatol. 2012;31:1\u201312.","journal-title":"Clin Rheumatol"},{"key":"259_CR36","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1001\/archneur.61.10.1523","volume":"61","author":"R Alvarez-Lafuente","year":"2004","unstructured":"Alvarez-Lafuente R, De las Heras V, Bartolom\u00e9 M, Picazo JJ, Arroyo R. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch Neurol. 2004;61:1523\u20137.","journal-title":"Arch Neurol"},{"key":"259_CR37","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1086\/315893","volume":"182","author":"N Akhyani","year":"2000","unstructured":"Akhyani N, Berti R, Brennan MB, Soldan SS, Eaton JM, McFarland HF, et al. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis. 2000;182:1321\u20135.","journal-title":"J Infect Dis"},{"key":"259_CR38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-pharmtox-011613-135937","volume":"54","author":"S Goldman","year":"2014","unstructured":"Goldman S. Environmental toxins and Parkinson\u2019s disease. Annu Rev Pharmacol Toxicol. 2014;54:141\u201364.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"259_CR39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/187221309787158371","volume":"3","author":"N Khansari","year":"2009","unstructured":"Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov. 2009;3:73\u201380.","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"259_CR40","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1158\/1535-7163.MCT-09-0383","volume":"8","author":"SP Tabruyn","year":"2009","unstructured":"Tabruyn SP, M\u00e9met S, Av\u00e9 P, Verhaeghe C, Mayo KH, Struman I, et al. NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Mol Cancer Ther. 2009;8:2645\u201354.","journal-title":"Mol Cancer Ther"},{"key":"259_CR41","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1097-2765(03)00390-3","volume":"12","author":"C Schmidt","year":"2003","unstructured":"Schmidt C, Peng B, Li Z, Sclabas GM, Fujioka S, Niu J, et al. Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation. Mol Cell. 2003;12:1287\u2013300.","journal-title":"Mol Cell"},{"key":"259_CR42","first-page":"490804","volume":"2012","author":"M Sultani","year":"2012","unstructured":"Sultani M, Stringer AM, Bowen JM, Gibson RJ. Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract. 2012;2012:490804.","journal-title":"Chemother Res Pract"},{"key":"259_CR43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/01.ATV.0000251615.61858.33","volume":"27","author":"S Nakata","year":"2007","unstructured":"Nakata S, Tsutsui M, Shimokawa H, Yamashita T, Tanimoto A, Tasaki H, et al. Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt\/NF-kappaB pathway. Arterioscler Thromb Vasc Biol. 2007;27:92\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"259_CR44","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1074\/jbc.M506172200","volume":"281","author":"J Anrather","year":"2006","unstructured":"Anrather J, Racchumi G, Iadecola C. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem. 2006;281:5657\u201367.","journal-title":"J Biol Chem"},{"key":"259_CR45","first-page":"3","volume":"5","author":"ST Sonis","year":"2007","unstructured":"Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007;5:3\u201311.","journal-title":"J Support Oncol"},{"key":"259_CR46","first-page":"21","volume":"2","author":"ST Sonis","year":"2004","unstructured":"Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2:21\u201332. discussion 35-6.","journal-title":"J Support Oncol"},{"key":"259_CR47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2010.178","volume":"21","author":"MJ Morgan","year":"2011","unstructured":"Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-\u03baB signaling. Cell Res. 2011;21:103\u201315.","journal-title":"Cell Res"},{"key":"259_CR48","first-page":"7","volume":"32","author":"M Maes","year":"2011","unstructured":"Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression\u2019s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett. 2011;32:7\u201324.","journal-title":"Neuro Endocrinol Lett"},{"key":"259_CR49","first-page":"615","volume":"27","author":"M Maes","year":"2006","unstructured":"Maes M, Mihaylova I, Leunis JC. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett. 2006;27:615\u201321.","journal-title":"Neuro Endocrinol Lett"},{"key":"259_CR50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2796.2000.00742.x","volume":"248","author":"H Kuper","year":"2000","unstructured":"Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171\u201383.","journal-title":"J Intern Med"},{"key":"259_CR51","first-page":"75","volume":"2","author":"S Miranda-Hernandez","year":"2013","unstructured":"Miranda-Hernandez S, Baxter AG. Role of toll-like receptors in multiple sclerosis. Am J Clin Exp Immunol. 2013;2:75\u201393.","journal-title":"Am J Clin Exp Immunol"},{"key":"259_CR52","doi-asserted-by":"crossref","unstructured":"Horton C, Pan Z, Farris A. Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm. 2010; 2010. doi:10.1155\/2010\/498980.","DOI":"10.1155\/2010\/498980"},{"key":"259_CR53","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/brain\/awp046","volume":"132","author":"DJ Mahad","year":"2009","unstructured":"Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, et al. Mitochondrial changes within axons in multiple sclerosis. Brain. 2009;132:1161\u201374.","journal-title":"Brain"},{"key":"259_CR54","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.20736","volume":"59","author":"R Dutta","year":"2006","unstructured":"Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59:478\u201389.","journal-title":"Ann Neurol"},{"key":"259_CR55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1352458510364196","volume":"16","author":"G Lazzarino","year":"2010","unstructured":"Lazzarino G, Amorini AM, Eikelenboom MJ, Killestein J, Belli A, Di Pietro V, et al. Cerebrospinal fluid ATP metabolites in multiple sclerosis. Mult Scler. 2010;16:549\u201354.","journal-title":"Mult Scler"},{"key":"259_CR56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11011-013-9435-x","volume":"29","author":"G Morris","year":"2014","unstructured":"Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis\/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis. 2014;29:19\u201336.","journal-title":"Metab Brain Dis"},{"key":"259_CR57","first-page":"208","volume":"5","author":"NE Booth","year":"2012","unstructured":"Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS). Int J Clin Exp Med. 2012;5:208\u201320.","journal-title":"Int J Clin Exp Med"},{"key":"259_CR58","first-page":"1","volume":"6","author":"S Myhill","year":"2013","unstructured":"Myhill S, Booth NE, McLaren-Howard J. Targeting mitochondrial dysfunction in the treatment of Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS) - a clinical audit. Int J Clin Exp Med. 2013;6:1\u201315.","journal-title":"Int J Clin Exp Med"},{"key":"259_CR59","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/sj.bjp.0702940","volume":"128","author":"WM Behan","year":"1999","unstructured":"Behan WM, McDonald M, Darlington LG, Stone TW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol. 1999;128:1754\u201360.","journal-title":"Br J Pharmacol"},{"key":"259_CR60","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2796.2009.02160.x","volume":"267","author":"DE Jones","year":"2010","unstructured":"Jones DE, Hollingsworth KG, Taylor R, Blamire AM, Newton JL. Abnormalities in pH handling by peripheral muscle and potential regulation by the autonomic nervous system in chronic fatigue syndrome. J Intern Med. 2010;267:394\u2013401.","journal-title":"J Intern Med"},{"key":"259_CR61","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2362.2010.02310.x","volume":"40","author":"KG Hollingsworth","year":"2010","unstructured":"Hollingsworth KG, Jones DE, Taylor R, Blamire AM, Newton JL. Impaired cardiovascular response to standing in chronic fatigue syndrome. Eur J Clin Invest. 2010;40:608\u201315.","journal-title":"Eur J Clin Invest"},{"key":"259_CR62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.brainres.2007.10.061","volume":"1189","author":"WD Parker Jr","year":"2008","unstructured":"Parker Jr WD, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson\u2019s disease frontal cortex. Brain Res. 2008;1189:215\u20138.","journal-title":"Brain Res"},{"key":"259_CR63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mds.870120103","volume":"12","author":"C Blake","year":"1997","unstructured":"Blake C, Spitz E, Leehey M, Hoffer B, Boyson S. Platelet mitochondrial respiratory chain function in Parkinson\u2019s disease. Mov Disord. 1997;12:3\u20138.","journal-title":"Mov Disord"},{"key":"259_CR64","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4103\/0028-3886.28112","volume":"54","author":"S Shinde","year":"2006","unstructured":"Shinde S, Pasupathy K. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson\u2019s disease: preliminary study. Neurol India. 2006;54:390\u20133.","journal-title":"Neurol India"},{"key":"259_CR65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/NDT.S44282","volume":"9","author":"EH Tobe","year":"2013","unstructured":"Tobe EH. Mitochondrial dysfunction, oxidative stress, and major depressive disorder. Neuropsychiatr Dis Treat. 2013;9:567\u201373.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"259_CR66","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrn3229","volume":"13","author":"H Manji","year":"2012","unstructured":"Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M, et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci. 2012;13:293\u2013307.","journal-title":"Nat Rev Neurosci"},{"key":"259_CR67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-60761-720-4_4","volume":"900","author":"A Perl","year":"2012","unstructured":"Perl A, Hanczko R, Doherty E. Assessment of mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. Methods Mol Biol. 2012;900:61\u201389.","journal-title":"Methods Mol Biol"},{"key":"259_CR68","first-page":"87","volume":"102","author":"A Perl","year":"2004","unstructured":"Perl A, Nagy G, Gergely P, Puskas F, Qian Y, Banki K. Apoptosis and mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. Methods Mol Med. 2004;102:87\u2013114.","journal-title":"Methods Mol Med"},{"key":"259_CR69","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.freeradbiomed.2007.02.026","volume":"42","author":"G Nagy","year":"2007","unstructured":"Nagy G, Koncz A, Fernandez D, Perl A. Nitric oxide, mitochondrial hyperpolarization, and T cell activation. Free Radic Biol Med. 2007;42:1625\u201331.","journal-title":"Free Radic Biol Med"},{"key":"259_CR70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10715762.2012.748904","volume":"47","author":"G Pagano","year":"2013","unstructured":"Pagano G, Castello G, Pallard\u00f3 FV. Sj\u00f8gren\u2019s syndrome-associated oxidative stress and mitochondrial dysfunction: prospects for chemoprevention trials. Free Radic Res. 2013;47:71\u20133.","journal-title":"Free Radic Res"},{"key":"259_CR71","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/art.37799","volume":"65","author":"B Cillero-Pastor","year":"2013","unstructured":"Cillero-Pastor B, Eijkel GB, Kiss A, Blanco FJ, Heeren RM. Matrix-assisted laser desorption ionization-imaging mass spectrometry: a new methodology to study human osteoarthritic cartilage. Arthritis Rheum. 2013;65:710\u201320.","journal-title":"Arthritis Rheum"},{"key":"259_CR72","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar2463","volume":"10","author":"SB Abramson","year":"2008","unstructured":"Abramson SB. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther. 2008;10:S2.","journal-title":"Arthritis Res Ther"},{"key":"259_CR73","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1038\/tp.2014.15","volume":"4","author":"S Rose","year":"2014","unstructured":"Rose S, Frye RE, Slattery J, Wynne R, Tippett M, Melnyk S, et al. Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines. Transl Psychiatry. 2014;4:e377.","journal-title":"Transl Psychiatry"},{"key":"259_CR74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1756-6606-5-35","volume":"5","author":"Y Imaizumi","year":"2012","unstructured":"Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, et al. Mitochondrial dysfunction associated with increased oxidative stress and \u03b1-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain. 2012;5:35.","journal-title":"Mol Brain"},{"key":"259_CR75","first-page":"646354","volume":"2012","author":"H Cui","year":"2012","unstructured":"Cui H, Kong Y, Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct. 2012;2012:646354.","journal-title":"J Signal Transduct"},{"key":"259_CR76","first-page":"64","volume":"14","author":"Y Lapierre","year":"2007","unstructured":"Lapierre Y, Hum S. Treating fatigue. Int MS J. 2007;14:64\u201371.","journal-title":"Int MS J"},{"key":"259_CR77","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1191\/1352458503ms904oa","volume":"9","author":"R Bakshi","year":"2003","unstructured":"Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler. 2003;9:219\u201327.","journal-title":"Mult Scler"},{"key":"259_CR78","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/1352458508097466","volume":"15","author":"E Patrick","year":"2009","unstructured":"Patrick E, Christodoulou C, Krupp LB, New York State MS Consortium. Longitudinal correlates of fatigue in multiple sclerosis. Mult Scler. 2009;15:258\u201361.","journal-title":"Mult Scler"},{"key":"259_CR79","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1191\/1352458502ms839oa","volume":"8","author":"P Flachenecker","year":"2002","unstructured":"Flachenecker P, K\u00fcmpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler. 2002;8:523\u20136.","journal-title":"Mult Scler"},{"key":"259_CR80","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1191\/135245800678827572","volume":"6","author":"J Iriarte","year":"2000","unstructured":"Iriarte J, Subira ML, Castro P. Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors. Mult Scler. 2000;6:124\u201330.","journal-title":"Mult Scler"},{"key":"259_CR81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1191\/1352458505ms1148oa","volume":"11","author":"N Tellez","year":"2005","unstructured":"Tellez N, Rio J, Tintor\u00e9 M, Nos C, Gal\u00e1n I, Montalban X. Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler. 2005;11:198\u2013202.","journal-title":"Mult Scler"},{"key":"259_CR82","doi-asserted-by":"crossref","first-page":"708659","DOI":"10.1155\/2013\/708659","volume":"2013","author":"GG Ortiz","year":"2013","unstructured":"Ortiz GG, Pacheco-Mois\u00e9s FP, Bitzer-Quintero OK, Ram\u00edrez-Anguiano AC, Flores-Alvarado LJ, Ram\u00edrez-Ram\u00edrez V, et al. Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol. 2013;2013:708659.","journal-title":"Clin Dev Immunol"},{"key":"259_CR83","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1177\/1352458514523496","volume":"20","author":"M Nakamura","year":"2014","unstructured":"Nakamura M, Matsuoka T, Chihara N, Miyake S, Sato W, Araki M, et al. Differential effects of fingolimod on B-cell populations in multiple sclerosis. Mult Scler. 2014;20:1371\u201380.","journal-title":"Mult Scler"},{"key":"259_CR84","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676\u201388.","journal-title":"N Engl J Med"},{"key":"259_CR85","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"259_CR86","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1742-2094-9-215","volume":"9","author":"J Romme Christensen","year":"2012","unstructured":"Romme Christensen J, B\u00f6rnsen L, Hesse D, Krakauer M, S\u00f8rensen PS, S\u00f8ndergaard HB, et al. Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. J Neuroinflammation. 2012;9:215.","journal-title":"J Neuroinflammation"},{"key":"259_CR87","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-0404.1988.tb03663.x","volume":"78","author":"J Beck","year":"1988","unstructured":"Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations. Acta Neurol Scand. 1988;78:318\u201323.","journal-title":"Acta Neurol Scand"},{"key":"259_CR88","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0165-5728(91)90073-G","volume":"32","author":"D Maimone","year":"1991","unstructured":"Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991;32:67\u201374.","journal-title":"J Neuroimmunol"},{"key":"259_CR89","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1097-4547(19960815)45:4<322::AID-JNR1>3.0.CO;2-B","volume":"45","author":"V Navikas","year":"1996","unstructured":"Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res. 1996;45:322\u201333.","journal-title":"J Neurosci Res"},{"key":"259_CR90","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/jnnp.2010.230029","volume":"82","author":"SM Gold","year":"2011","unstructured":"Gold SM, Kr\u00fcger S, Ziegler KJ, Krieger T, Schulz KH, Otte C, et al. Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry. 2011;82:814\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/jnnp.2005.065805","volume":"77","author":"C Heesen","year":"2006","unstructured":"Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry. 2006;77:34\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR92","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1191\/1352458504ms991oa","volume":"10","author":"P Flachenecker","year":"2004","unstructured":"Flachenecker P, Bihler I, Weber F, Gottschalk M, Toyka KV, Rieckmann P. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler. 2004;10:165\u20139.","journal-title":"Mult Scler"},{"key":"259_CR93","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.neuint.2010.07.002","volume":"57","author":"P Nagyoszi","year":"2010","unstructured":"Nagyoszi P, Wilhelm I, Farkas AE, Fazakas C, Dung NT, Hask\u00f3 J, et al. Expression and regulation of toll-like receptors in cerebral endothelial cells. Neurochem Int. 2010;57:556\u201364.","journal-title":"Neurochem Int"},{"key":"259_CR94","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1189\/jlb.1207844","volume":"84","author":"A Andersson","year":"2008","unstructured":"Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 2008;84:1248\u201355.","journal-title":"J Leukoc Biol"},{"key":"259_CR95","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jnen\/61.11.1013","volume":"61","author":"M Bsibsi","year":"2002","unstructured":"Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol. 2002;61:1013\u201321.","journal-title":"J Neuropathol Exp Neurol"},{"key":"259_CR96","doi-asserted-by":"crossref","first-page":"961863","DOI":"10.1155\/2014\/961863","volume":"2014","author":"M Gironi","year":"2014","unstructured":"Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, et al. Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. J Immunol Res. 2014;2014:961863.","journal-title":"J Immunol Res"},{"key":"259_CR97","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinbiochem.2011.09.021","volume":"45","author":"E Miller","year":"2012","unstructured":"Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I. Oxidative modification of patient\u2019s plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem. 2012;45:26\u201330.","journal-title":"Clin Biochem"},{"key":"259_CR98","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2008.06.029","volume":"274","author":"RE Gonsette","year":"2008","unstructured":"Gonsette RE. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci. 2008;274:48\u201353.","journal-title":"J Neurol Sci"},{"key":"259_CR99","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.freeradbiomed.2011.04.043","volume":"51","author":"C Stavropoulou","year":"2011","unstructured":"Stavropoulou C, Zachaki S, Alexoudi A, Chatzi I, Georgakakos VN, Terzoudi GI, et al. The C609T inborn polymorphism in NAD(P)H:quinone oxidoreductase 1 is associated with susceptibility to multiple sclerosis and affects the risk of development of the primary progressive form of the disease. Free Radic Biol Med. 2011;51:713\u20138.","journal-title":"Free Radic Biol Med"},{"key":"259_CR100","doi-asserted-by":"crossref","first-page":"e65184","DOI":"10.1371\/journal.pone.0065184","volume":"8","author":"A Fiorini","year":"2013","unstructured":"Fiorini A, Koudriavtseva T, Bucaj E, Coccia R, Foppoli C, Giorgi A, et al. Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One. 2013;8:e65184.","journal-title":"PLoS One"},{"key":"259_CR101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jns.2012.07.045","volume":"321","author":"SR Oliveira","year":"2012","unstructured":"Oliveira SR, Kallaur AP, Sim\u00e3o AN, Morimoto HK, Lopes J, Panis C, et al. Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci. 2012;321:49\u201353.","journal-title":"J Neurol Sci"},{"key":"259_CR102","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2013.11.006","volume":"337","author":"S Ljubisavljevic","year":"2014","unstructured":"Ljubisavljevic S, Stojanovic I, Cvetkovic T, Vojinovic S, Stojanov D, Stojanovic D, et al. Erythrocytes\u2019 antioxidative capacity as a potential marker of oxidative stress intensity in neuroinflammation. J Neurol Sci. 2014;337:8\u201313.","journal-title":"J Neurol Sci"},{"key":"259_CR103","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1523\/JNEUROSCI.5804-08.2009","volume":"29","author":"D Centonze","year":"2009","unstructured":"Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci. 2009;29:3442\u201352.","journal-title":"J Neurosci"},{"key":"259_CR104","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-510X(00)00343-9","volume":"177","author":"F Lu","year":"2000","unstructured":"Lu F, Selak M, O\u2019Connor J, Croul S, Lorenzana C, Butunoi C, et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci. 2000;177:95\u2013103.","journal-title":"J Neurol Sci"},{"key":"259_CR105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2990.2008.00987.x","volume":"34","author":"D Mahad","year":"2008","unstructured":"Mahad D, Lassmann H, Turnbull D. Review: mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol. 2008;34:577\u201389.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"259_CR106","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1177\/1352458513516528","volume":"20","author":"S Reinke","year":"2014","unstructured":"Reinke S, Broadhurst D, Sykes B, Baker G, Catz I, Warren K, et al. Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis. Mult Scler. 2014;20:1396\u2013400.","journal-title":"Mult Scler"},{"key":"259_CR107","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1371\/journal.pone.0000595","volume":"2","author":"NW Lutz","year":"2007","unstructured":"Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva JP, et al. Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007;2:e595.","journal-title":"PLoS One"},{"key":"259_CR108","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2174\/138920111795909122","volume":"12","author":"NW Lutz","year":"2011","unstructured":"Lutz NW, Cozzone PJ. Metabolic profiling in multiple sclerosis and other disorders by quantitative analysis of cerebrospinal fluid using nuclear magnetic resonance spectroscopy. Curr Pharm Biotechnol. 2011;12:1016\u201325.","journal-title":"Curr Pharm Biotechnol"},{"key":"259_CR109","doi-asserted-by":"crossref","first-page":"78811","DOI":"10.1371\/journal.pone.0078811","volume":"8","author":"H Genova","year":"2013","unstructured":"Genova H, Rajagopalan V, DeLuca J, Das A, Binder A, Arjunan A, et al. Examination of cognitive fatigue in multiple sclerosis using functional magnetic resonance imaging and diffusion tensor imaging. PLos One. 2013;8:78811.","journal-title":"PLos One"},{"key":"259_CR110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/02699050902788519","volume":"23","author":"AD Kohl","year":"2009","unstructured":"Kohl AD, Wylie GR, Genova HM, Hillary FG, Deluca J. The neural correlates of cognitive fatigue in traumatic brain injury using functional MRI. Brain Inj. 2009;23:420\u201332.","journal-title":"Brain Inj"},{"key":"259_CR111","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pmr.2008.12.007","volume":"20","author":"J DeLuca","year":"2009","unstructured":"DeLuca J, Genova H, Capili E, Wylie G. Functional neuroimaging of fatigue. Phys Med Rehabil Clin N Am. 2009;20:325\u201337.","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"259_CR112","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(04)15794-2","volume":"363","author":"A Chaudhuri","year":"2004","unstructured":"Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet. 2004;363:978\u201388.","journal-title":"Lancet"},{"key":"259_CR113","first-page":"609694","volume":"2014","author":"S Messina","year":"2014","unstructured":"Messina S, Patti F. Gray matters in multiple sclerosis: cognitive impairment and structural MRI. Mult Scler Int. 2014;2014:609694.","journal-title":"Mult Scler Int"},{"key":"259_CR114","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3174\/ajnr.A1944","volume":"31","author":"M Filippi","year":"2010","unstructured":"Filippi M, Rocca M. MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy. AJNR Am J Neuroradiol. 2010;31:1171\u20137.","journal-title":"AJNR Am J Neuroradiol"},{"key":"259_CR115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.neuroimage.2008.04.173","volume":"42","author":"A Ceccarelli","year":"2008","unstructured":"Ceccarelli A, Rocca M, Pagani E, Colombo B, Martinelli V, Comi G, et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage. 2008;42:315\u201322.","journal-title":"Neuroimage"},{"key":"259_CR116","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/jnnp.2007.134825","volume":"79","author":"R Henry","year":"2008","unstructured":"Henry R, Shieh M, Okuda D, Evangelista A, Gorno-Tempini M, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry. 2008;79:1236\u201344.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR117","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/brain\/awh126","volume":"127","author":"C Dalton","year":"2004","unstructured":"Dalton C, Chard D, Davies G, Miszkiel K, Altmann D, Fernando K, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain. 2004;127:1101\u20137.","journal-title":"Brain"},{"key":"259_CR118","doi-asserted-by":"crossref","first-page":"66117","DOI":"10.1371\/journal.pone.0066117","volume":"8","author":"S Schutzer","year":"2013","unstructured":"Schutzer S, Angel T, Liu T, Schepmoes A, Xie F, Bergquist J, et al. Gray matter is targeted in first-attack multiple sclerosis. PLoS One. 2013;8:66117.","journal-title":"PLoS One"},{"key":"259_CR119","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/msj.20247","volume":"78","author":"M Inglese","year":"2011","unstructured":"Inglese M, Oesingmann N, Casaccia P, Fleysher L. Progressive multiple sclerosis and gray matter pathology: an MRI perspective. Mt Sinai J Med. 2011;78:258\u201367.","journal-title":"Mt Sinai J Med"},{"key":"259_CR120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2377-12-10","volume":"12","author":"D Horakova","year":"2012","unstructured":"Horakova D, Kalincik T, Dusankova J, Dolezal O. Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurol. 2012;12:10.","journal-title":"BMC Neurol"},{"key":"259_CR121","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2013-305612","volume":"85","author":"L Debernard","year":"2013","unstructured":"Debernard L, Melzer T, Van Stockum S, Graham C, Wheeler-Kingshott C, Dalrymple-Alford J, et al. Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;85:544\u201351.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR122","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archneurol.2009.174","volume":"66","author":"M Calabrese","year":"2009","unstructured":"Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol. 2009;66:1144\u201350.","journal-title":"Arch Neurol"},{"key":"259_CR123","first-page":"6","volume":"82","author":"A Damasceno","year":"2014","unstructured":"Damasceno A, Damasceno B, Cendes F. Cerebellar and brain gray-matter damage predicts fatigue in multiple sclerosis (P6. 120). Neurology. 2014;82:6\u2013120.","journal-title":"Neurology"},{"key":"259_CR124","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/archneurol.2010.48","volume":"67","author":"C Pellicano","year":"2010","unstructured":"Pellicano C, Gallo A, Li X, Ikonomidou VN, Evangelou IE, Ohayon JM, et al. Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Arch Neurol. 2010;67:447\u201353.","journal-title":"Arch Neurol"},{"key":"259_CR125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archneur.64.2.196","volume":"64","author":"M Inglese","year":"2007","unstructured":"Inglese M, Park S, Johnson G, Babb J, Miles L, Jaggi H, et al. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3\u00a0T. Arch Neurol. 2007;64:196\u2013202.","journal-title":"Arch Neurol"},{"key":"259_CR126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jns.2007.07.004","volume":"263","author":"G Tedeschi","year":"2007","unstructured":"Tedeschi G, Dinacci D, Lavorgna L, Prinster A, Savettieri G, Quattrone A, et al. Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. J Neurol Sci. 2007;263:15\u20139.","journal-title":"J Neurol Sci"},{"key":"259_CR127","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.48.6.1566","volume":"48","author":"U Roelcke","year":"1997","unstructured":"Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, Ammann W, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18\u00a0F-fluorodeoxyglucose positron emission tomography study. Neurology. 1997;48:1566\u201371.","journal-title":"Neurology"},{"key":"259_CR128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jon199884228","volume":"8","author":"R Bakshi","year":"1998","unstructured":"Bakshi R, Miletich RS, Kinkel PR, Emmet ML, Kinkel WR. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging. 1998;8:228\u201334.","journal-title":"J Neuroimaging"},{"key":"259_CR129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1212\/WNL.54.3.558","volume":"54","author":"M Blinkenberg","year":"2000","unstructured":"Blinkenberg M, Rune K, Jensen CV, Ravnborg M, Kyllingsbaek S, Holm S, et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology. 2000;54:558\u201364.","journal-title":"Neurology"},{"key":"259_CR130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00234-007-0304-3","volume":"50","author":"N Tellez","year":"2008","unstructured":"Tellez N, Alonso J, Rio J, Tintore M, Nos C, Montalban X, et al. The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology. 2008;50:17\u201323.","journal-title":"Neuroradiology"},{"key":"259_CR131","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/1352458510376405","volume":"16","author":"M Calabrese","year":"2010","unstructured":"Calabrese M, Rinaldi F, Grossi P, Mattisi I, Bernardi V, Favaretto A, et al. Basal ganglia and frontal\/parietal cortical atrophy is associated with fatigue in relapsing\u2013remitting multiple sclerosis. Mult Scler. 2010;16:1220\u20138.","journal-title":"Mult Scler"},{"key":"259_CR132","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jns.2012.12.014","volume":"333","author":"M Moreno","year":"2013","unstructured":"Moreno M, Guo F, Ko E, Bannerman P, Soulika A, Pleasure D. Origins and significance of astrogliosis in the multiple sclerosis model, MOG peptide EAE. J Neurol Sci. 2013;333:55\u20139.","journal-title":"J Neurol Sci"},{"key":"259_CR133","first-page":"10","volume":"28","author":"C Brosnan","year":"2013","unstructured":"Brosnan C. Characteristics of a reactive astrogliosis in multiple sclerosis. Revista Espanola De Esclerosis Multiple. 2013;28:10\u20138. Available at: http:\/\/www.revistaesclerosis.es\/pdf\/partes\/v5_28dic13_02.pdf.","journal-title":"Revista Espanola De Esclerosis Multiple"},{"key":"259_CR134","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neulet.2013.10.012","volume":"565","author":"S Hostenbach","year":"2014","unstructured":"Hostenbach S, Cambron M, D\u2019haeseleer M, Kooijman R, De Keyser J. Astrocyte loss and astrogliosis in neuroinflammatory disorders. Neurosci Lett. 2014;565:39\u201341.","journal-title":"Neurosci Lett"},{"key":"259_CR135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-61779-452-0_3","volume":"814","author":"N Oberheim","year":"2012","unstructured":"Oberheim N, Goldman S, Nedergaard M. Heterogeneity of astrocytic form and function. Methods Mol Biol. 2012;814:23\u201345.","journal-title":"Methods Mol Biol"},{"key":"259_CR136","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fncel.2013.00038","volume":"7","author":"J Stobart","year":"2013","unstructured":"Stobart J, Anderson C. Multifunctional role of astrocytes as gatekeepers of neuronal energy supply. Front Cell Neurosci. 2013;7:38.","journal-title":"Front Cell Neurosci"},{"key":"259_CR137","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00401-009-0619-8","volume":"119","author":"M Sofroniew","year":"2010","unstructured":"Sofroniew M, Vinters H. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119:7\u201335.","journal-title":"Acta Neuropathol"},{"key":"259_CR138","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/jnnp-2014-307712","volume":"85","author":"L Haider","year":"2014","unstructured":"Haider L, Simeonidou C, Steinberger G, Hametner S, Grigoriadis N, Deretzi G, et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry. 2014;85:1386\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR139","first-page":"953","volume":"121","author":"K Fukuda","year":"1994","unstructured":"Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group Ann Intern Med. 1994;121:953\u20139.","journal-title":"International Chronic Fatigue Syndrome Study Group. Ann Intern Med"},{"key":"259_CR140","first-page":"185","volume":"34","author":"G Morris","year":"2013","unstructured":"Morris G, Maes M. Case definitions and diagnostic criteria for Myalgic Encephalomyelitis and Chronic fatigue Syndrome: from clinical-consensus to evidence-based case definitions. Neuro Endocrinol Lett. 2013;34:185\u201399.","journal-title":"Neuro Endocrinol Lett"},{"key":"259_CR141","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7326\/0003-4819-108-3-387","volume":"108","author":"GP Holmes","year":"1988","unstructured":"Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988;108:387\u20139.","journal-title":"Ann Intern Med"},{"key":"259_CR142","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.autrev.2008.08.003","volume":"8","author":"L Lorusso","year":"2009","unstructured":"Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev. 2009;8:287\u201391.","journal-title":"Autoimmun Rev"},{"key":"259_CR143","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1128\/jcm.28.6.1403-1410.1990","volume":"28","author":"NG Klimas","year":"1990","unstructured":"Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28:1403\u201310.","journal-title":"J Clin Microbiol"},{"key":"259_CR144","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jad.2011.09.004","volume":"136","author":"M Maes","year":"2012","unstructured":"Maes M, Twisk FN, Kubera M, Ringel K. Evidence for inflammation and activation of cell-mediated immunity in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS): increased interleukin-1, tumor necrosis factor-\u03b1, PMN-elastase, lysozyme and neopteri. J Affect Disord. 2012;136:933\u20139.","journal-title":"J Affect Disord"},{"key":"259_CR145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2249.2005.02935.x","volume":"142","author":"KJ Maher","year":"2005","unstructured":"Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol. 2005;142:505\u201311.","journal-title":"Clin Exp Immunol"},{"key":"259_CR146","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bbi.2010.04.012","volume":"24","author":"G Broderick","year":"2010","unstructured":"Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun. 2010;24:1209\u201317.","journal-title":"Brain Behav Immun"},{"key":"259_CR147","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1479-5876-10-88","volume":"10","author":"EW Brenu","year":"2012","unstructured":"Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome\/myalgic encephalomyelitis. J Transl Med. 2012;10:88.","journal-title":"J Transl Med"},{"key":"259_CR148","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1479-5876-9-81","volume":"9","author":"EW Brenu","year":"2011","unstructured":"Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, et al. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis. J Transl Med. 2011;9:81.","journal-title":"J Transl Med"},{"key":"259_CR149","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1023\/A:1020595709352","volume":"19","author":"RB Moss","year":"1999","unstructured":"Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. J Clin Immunol. 1999;19:314\u20136.","journal-title":"J Clin Immunol"},{"key":"259_CR150","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0091-6749(98)70090-9","volume":"102","author":"L Borish","year":"1998","unstructured":"Borish L, Schmaling K, DiClementi JD, Streib J, Negri J, Jones JF. Chronic fatigue syndrome: identification of distinct subgroups on the basis of allergy and psychologic variables. J Allergy Clin Immunol. 1998;102:222\u201330.","journal-title":"J Allergy Clin Immunol"},{"key":"259_CR151","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1093\/clinids\/18.Supplement_1.S147","volume":"18","author":"R Patarca","year":"1994","unstructured":"Patarca R, Klimas N, Lugtendorf S, Antoni M, Fletcher M. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis. 1994;18:S147\u201353.","journal-title":"Clin Infect Dis"},{"key":"259_CR152","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jpain.2009.06.003","volume":"10","author":"AR Light","year":"2009","unstructured":"Light AR, White AT, Hughen RW, Light KC. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J Pain. 2009;10:1099\u2013112.","journal-title":"J Pain"},{"key":"259_CR153","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/PSY.0b013e31824152ed","volume":"74","author":"AT White","year":"2012","unstructured":"White AT, Light AR, Hughen RW, Vanhaitsma TA, Light KC. Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls. Psychosom Med. 2012;74:46\u201354.","journal-title":"Psychosom Med"},{"key":"259_CR154","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1755-8794-2-38","volume":"2","author":"JW Gow","year":"2009","unstructured":"Gow JW, Hagan S, Herzyk P, Cannon C, Behan PO, Chaudhuri A. A gene signature for post-infectious chronic fatigue syndrome. BMC Med Genomics. 2009;2:38.","journal-title":"BMC Med Genomics"},{"key":"259_CR155","first-page":"715","volume":"30","author":"M Maes","year":"2009","unstructured":"Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis\/chronic fatigue syndrome. Neuro Endocrinol Lett. 2009;30:715\u201322.","journal-title":"Neuro Endocrinol Lett"},{"key":"259_CR156","first-page":"470","volume":"30","author":"M Maes","year":"2009","unstructured":"Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME\/CFS due to cardiovascular disorder. Neuro Endocrinol Lett. 2009;30:470\u20136.","journal-title":"Neuro Endocrinol Lett"},{"key":"259_CR157","doi-asserted-by":"crossref","first-page":"SC11","DOI":"10.12659\/MSM.881699","volume":"17","author":"M Maes","year":"2011","unstructured":"Maes M, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides as a marker of oxidative stress in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). Med Sci Monit. 2011;17:SC11\u20135.","journal-title":"Med Sci Monit"},{"key":"259_CR158","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.freeradbiomed.2005.04.020","volume":"39","author":"G Kennedy","year":"2005","unstructured":"Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med. 2005;39:584\u20139.","journal-title":"Free Radic Biol Med"},{"key":"259_CR159","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/nbm.2772","volume":"25","author":"DC Shungu","year":"2012","unstructured":"Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP, et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 2012;25:1073\u201387.","journal-title":"NMR Biomed"},{"key":"259_CR160","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00380-009-1206-6","volume":"25","author":"K Miwa","year":"2010","unstructured":"Miwa K, Fujita M. Fluctuation of serum vitamin E (alpha-tocopherol) concentrations during exacerbation and remission phases in patients with chronic fatigue syndrome. Heart Vessels. 2010;25:319\u201323.","journal-title":"Heart Vessels"},{"key":"259_CR161","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10974-008-9128-y","volume":"28","author":"S Fulle","year":"2007","unstructured":"Fulle S, Pietrangelo T, Mancinelli R, Saggini R, Fan\u00f2 G. Specific correlations between muscle oxidative stress and chronic fatigue syndrome: a working hypothesis. J Muscle Res Cell Motil. 2007;28:355\u201362.","journal-title":"J Muscle Res Cell Motil"},{"key":"259_CR162","first-page":"1","volume":"2","author":"S Myhill","year":"2009","unstructured":"Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2:1\u201316.","journal-title":"Int J Clin Exp Med"},{"key":"259_CR163","first-page":"36","volume":"15","author":"WM Behan","year":"1995","unstructured":"Behan WM, More IA, Downie I, Gow JW. Mitochondrial studies in the chronic fatigue syndrome. EOS Riv Immunol Immunofarmacol. 1995;15:36\u20139.","journal-title":"EOS Riv Immunol Immunofarmacol"},{"key":"259_CR164","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/CS19980372","volume":"97","author":"KK McCully","year":"1999","unstructured":"McCully KK, Natelson BH. Impaired oxygen delivery to muscle in chronic fatigue syndrome. Clin Sci (Lond). 1999;97:603\u20138. discussion 611-613.","journal-title":"Clin Sci (Lond)"},{"key":"259_CR165","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/(SICI)1097-4598(199605)19:5<621::AID-MUS10>3.0.CO;2-Q","volume":"19","author":"KK McCully","year":"1996","unstructured":"McCully KK, Natelson BH, Iotti S, Sisto S, Leigh Jr JS. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve. 1996;19:621\u20135.","journal-title":"Muscle Nerve"},{"key":"259_CR166","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1378\/chest.102.6.1716","volume":"102","author":"R Wong","year":"1992","unstructured":"Wong R, Lopaschuk G, Zhu G, Walker D, Catellier D, Burton D, et al. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest. 1992;102:1716\u201322.","journal-title":"Chest"},{"key":"259_CR167","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(84)91871-3","volume":"1","author":"DL Arnold","year":"1984","unstructured":"Arnold DL, Bore PJ, Radda GK, Styles P, Taylor DJ. Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion\/fatigue syndrome. A 31P nuclear magnetic resonance study. Lancet. 1984;1:1367\u20139.","journal-title":"Lancet"},{"key":"259_CR168","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/jnnp.74.10.1382","volume":"74","author":"RJ Lane","year":"2003","unstructured":"Lane RJ, Soteriou BA, Zhang H, Archard LC. Enterovirus related metabolic myopathy: a postviral fatigue syndrome. J Neurol Neurosurg Psychiatry. 2003;74:1382\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR169","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbacli.2014.04.001","volume":"1","author":"K Filler","year":"2014","unstructured":"Filler K, Lyon D, Bennett J, McCain N, Elswisk R, Lukkahatai N, et al. Association of mitochondrial dysfunction and fatigue: a review of the literature. BBA Clin. 2014;1:12\u201323.","journal-title":"BBA Clin"},{"key":"259_CR170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1479-5876-8-93","volume":"8","author":"RC Vermeulen","year":"2010","unstructured":"Vermeulen RC, Kurk RM, Visser FC, Sluiter W, Scholte HR. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J Transl Med. 2010;8:93.","journal-title":"J Transl Med"},{"key":"259_CR171","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-12-20","volume":"12","author":"RC Vermeulen","year":"2014","unstructured":"Vermeulen RC, Vermeulen van Eck IW. Decreased oxygen extraction during cardiopulmonary exercise test in patients with chronic fatigue syndrome. J Transl Med. 2014;12:20.","journal-title":"J Transl Med"},{"key":"259_CR172","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/nbm.1315","volume":"22","author":"SJ Mathew","year":"2009","unstructured":"Mathew SJ, Mao X, Keegan KA, Levine SM, Smith EL, Heier LA, et al. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0\u00a0T (1)H MRS imaging study. NMR Biomed. 2009;22:251\u20138.","journal-title":"NMR Biomed"},{"key":"259_CR173","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/nbm.1512","volume":"23","author":"JW Murrough","year":"2010","unstructured":"Murrough JW, Mao X, Collins KA, Kelly C, Andrade G, Nestadt P, et al. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0\u00a0T. II: comparison with major depressive disorder. NMR Biomed. 2010;23:643\u201350.","journal-title":"NMR Biomed"},{"key":"259_CR174","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1475-097X.2006.00649.x","volume":"26","author":"K Yoshiuchi","year":"2006","unstructured":"Yoshiuchi K, Farkas J, Natelson B. Patients with chronic fatigue syndrome have reduced absolute cortical blood flow. Clin Physiol Funct Imaging. 2006;26:83\u20136.","journal-title":"Clin Physiol Funct Imaging"},{"key":"259_CR175","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1192\/bjp.176.6.550","volume":"176","author":"S Machale","year":"2000","unstructured":"Machale S, Lawrie S, Cavanagh JT, Glabus MF, Murray CL, Goodwin GM, et al. Cerebral perfusion in chronic fatigue syndrome and depression. Br J Psychiatry. 2000;176:550\u20136.","journal-title":"Br J Psychiatry"},{"key":"259_CR176","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00006231-199213100-00011","volume":"13","author":"M Ichise","year":"1992","unstructured":"Ichise M, Salit IE, Abbey SE, Chung DG, Gray B, Kirsh JC, et al. Assessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome. Nucl Med Commun. 1992;13:767\u201372.","journal-title":"Nucl Med Commun"},{"key":"259_CR177","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.neuroimage.2005.02.037","volume":"26","author":"FP de Lange","year":"2005","unstructured":"de Lange FP, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JW, Toni I. Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage. 2005;26:777\u201381.","journal-title":"Neuroimage"},{"key":"259_CR178","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1093\/brain\/awn140","volume":"131","author":"FP de Lange","year":"2008","unstructured":"de Lange FP, Koers A, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JW, et al. Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain. 2008;131:2172\u201380.","journal-title":"Brain"},{"key":"259_CR179","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2377-4-14","volume":"4","author":"T Okada","year":"2004","unstructured":"Okada T, Tanaka M, Kuratsune H, Watanabe Y, Sadato N. Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome. BMC Neurol. 2004;4:14.","journal-title":"BMC Neurol"},{"key":"259_CR180","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1523\/JNEUROSCI.0098-07.2007","volume":"27","author":"A Kuchinad","year":"2007","unstructured":"Kuchinad A, Schweinhardt P, Seminowicz D, Wood P, Chizh B, Bushnell M. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci. 2007;27:4004\u20137.","journal-title":"J Neurosci"},{"key":"259_CR181","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1259\/bjr\/93889091","volume":"85","author":"BK Puri","year":"2011","unstructured":"Puri BK, Jakeman PM, Agour M, Gunatilake KD, Fernando KA, Gurusinghe AI, et al. Regional grey and white matter volumetric changes in myalgic encephalomyelitis (chronic fatigue syndrome): a voxel-based morphometry 3-T MRI study. Br J Radiol. 2011;85:e270\u20133.","journal-title":"Br J Radiol"},{"key":"259_CR182","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuroimage.2007.02.033","volume":"36","author":"DB Cook","year":"2007","unstructured":"Cook DB, O\u2019Connor PJ, Lange G, Steffener J. Functional neuroimaging correlates of mental fatigue induced by cognition among chronic fatigue syndrome patients and controls. Neuroimage. 2007;36:108\u201322.","journal-title":"Neuroimage"},{"key":"259_CR183","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1017\/S0033291708003450","volume":"38","author":"X Caseras","year":"2008","unstructured":"Caseras X, Mataix-Cols D, Rimes KA, Giampietro V, Brammer M, Zelaya F, et al. The neural correlates of fatigue: an exploratory imaginal fatigue provocation study in chronic fatigue syndrome. Psychol Med. 2008;38:941\u201351.","journal-title":"Psychol Med"},{"key":"259_CR184","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp.74.7.922","volume":"74","author":"T Siessmeier","year":"2003","unstructured":"Siessmeier T, Nix WA, Hardt J, Schreckenberger M, Egle UT, Bartenstein P. Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 2003;74:922\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR185","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1016\/S0002-9343(98)00179-X","volume":"105","author":"U Tirelli","year":"1998","unstructured":"Tirelli U, Chierichetti F, Tavio M, Simonelli C, Bianchin G, Zanco P, et al. Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med. 1998;105:54S\u20138S.","journal-title":"Am J Med"},{"key":"259_CR186","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/nbm.1692","volume":"24","author":"LR Barnden","year":"2011","unstructured":"Barnden LR, Crouch B, Kwiatek R, Burnet R, Mernone A, Chryssidis S, et al. A brain MRI study of chronic fatigue syndrome: evidence of brainstem dysfunction and altered homeostasis. NMR Biomed. 2011;24:1302\u201312.","journal-title":"NMR Biomed"},{"key":"259_CR187","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/01.WNL.0000144277.06917.CC","volume":"63","author":"G Alves","year":"2004","unstructured":"Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology. 2004;63:1908\u201311.","journal-title":"Neurology"},{"key":"259_CR188","first-page":"S122","volume":"17","author":"S Pal","year":"2002","unstructured":"Pal S, Chaudhuri KR, Trenkwalder C, Forbes A, Bridgman K, DiMarco A. The parkinson\u2019s disease sleep scale (pdss): A new instrument for assessment of sleep, nocturnal disability and daytime sleepiness in parkinson\u2019s disease. Mov Disord. 2002;17:S122.","journal-title":"Mov Disord"},{"key":"259_CR189","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/mds.21240","volume":"22","author":"JH Friedman","year":"2007","unstructured":"Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, Lou JS, et al. Fatigue in Parkinson\u2019s disease: a review. Mov Disord. 2007;22:297\u2013308.","journal-title":"Mov Disord"},{"key":"259_CR190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02257678","volume":"5","author":"JJ van Hilten","year":"1993","unstructured":"van Hilten JJ, Weggeman M, van der Velde EA, Kerkhof GA, van Dijk JG, Roos RA. Sleep, excessive daytime sleepiness and fatigue in Parkinson\u2019s disease. J Neural Transm Park Dis Dement Sect. 1993;5:235\u201344.","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"259_CR191","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord. 2009;24:1641\u20139.","journal-title":"Mov Disord"},{"key":"259_CR192","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/jnnp.2008.159772","volume":"80","author":"P Hagell","year":"2009","unstructured":"Hagell P, Brundin L. Towards an understanding of fatigue in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80:489\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR193","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5:235\u201345.","journal-title":"Lancet Neurol"},{"key":"259_CR194","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/01.wnl.0000324862.29733.69","volume":"71","author":"G Schifitto","year":"2008","unstructured":"Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008;71:481\u20135.","journal-title":"Neurology"},{"key":"259_CR195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1600-0404.1999.tb00721.x","volume":"100","author":"RJ Dobbs","year":"1999","unstructured":"Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 1999;100:34\u201341.","journal-title":"Acta Neurol Scand"},{"key":"259_CR196","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0304-3940(95)12192-7","volume":"202","author":"D Blum-Degen","year":"1995","unstructured":"Blum-Degen D, M\u00fcller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer\u2019s and de novo Parkinson\u2019s disease patients. Neurosci Lett. 1995;202:17\u201320.","journal-title":"Neurosci Lett"},{"key":"259_CR197","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbi.2008.07.003","volume":"23","author":"M Reale","year":"2009","unstructured":"Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, et al. Peripheral cytokines profile in Parkinson\u2019s disease. Brain Behav Immun. 2009;23:55\u201363.","journal-title":"Brain Behav Immun"},{"key":"259_CR198","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archneur.58.10.1580","volume":"58","author":"K Hisanaga","year":"2001","unstructured":"Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y. Increase in peripheral CD4 bright\u2009+\u2009CD8 dull\u2009+\u2009T cells in Parkinson disease. Arch Neurol. 2001;58:1580\u20133.","journal-title":"Arch Neurol"},{"key":"259_CR199","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0165-5728(00)00422-7","volume":"113","author":"J Bas","year":"2001","unstructured":"Bas J, Calopa M, Mestre M, Mollev\u00ed DG, Cutillas B, Ambrosio S, et al. Lymphocyte populations in Parkinson\u2019s disease and in rat models of parkinsonism. J Neuroimmunol. 2001;113:146\u201352.","journal-title":"J Neuroimmunol"},{"key":"259_CR200","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.parkreldis.2005.07.005","volume":"11","author":"Y Baba","year":"2005","unstructured":"Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005;11:493\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"259_CR201","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jneuroim.2009.08.001","volume":"216","author":"P Scalzo","year":"2009","unstructured":"Scalzo P, K\u00fcmmer A, Cardoso F, Teixeira AL. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson\u2019s disease. J Neuroimmunol. 2009;216:122\u20135.","journal-title":"J Neuroimmunol"},{"key":"259_CR202","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.parkreldis.2008.05.014","volume":"15","author":"M Dufek","year":"2009","unstructured":"Dufek M, Hamanov\u00e1 M, Lokaj J, Goldemund D, Rektorov\u00e1 I, Mich\u00e1lkov\u00e1 Z, et al. Serum inflammatory biomarkers in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2009;15:318\u201320.","journal-title":"Parkinsonism Relat Disord"},{"key":"259_CR203","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/aje\/kwm260","volume":"167","author":"H Chen","year":"2008","unstructured":"Chen H, O\u2019Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson\u2019s disease. Am J Epidemiol. 2008;167:90\u20135.","journal-title":"Am J Epidemiol"},{"key":"259_CR204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2007.07.004","volume":"208","author":"MG Tansey","year":"2007","unstructured":"Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson\u2019s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol. 2007;208:1\u201325.","journal-title":"Exp Neurol"},{"key":"259_CR205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1326-4-47","volume":"4","author":"TC Frank-Cannon","year":"2009","unstructured":"Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener. 2009;4:47.","journal-title":"Mol Neurodegener"},{"key":"259_CR206","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5483\/BMBRep.2010.43.4.225","volume":"43","author":"YC Chung","year":"2010","unstructured":"Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, et al. The role of neuroinflammation on the pathogenesis of Parkinson\u2019s disease. BMB Rep. 2010;43:225\u201332.","journal-title":"BMB Rep"},{"key":"259_CR207","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.expneurol.2007.02.008","volume":"205","author":"E Esposito","year":"2007","unstructured":"Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson\u2019s disease. Exp Neurol. 2007;205:295\u2013312.","journal-title":"Exp Neurol"},{"key":"259_CR208","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-5-8","volume":"5","author":"JB Koprich","year":"2008","unstructured":"Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson\u2019s disease. J Neuroinflammation. 2008;5:8.","journal-title":"J Neuroinflammation"},{"key":"259_CR209","doi-asserted-by":"crossref","first-page":"e47387","DOI":"10.1371\/journal.pone.0047387","volume":"7","author":"D Lindqvist","year":"2012","unstructured":"Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with Parkinson\u2019s disease - correlations with inflammatory cytokines in serum. PLoS One. 2012;7:e47387.","journal-title":"PLoS One"},{"key":"259_CR210","first-page":"436813","volume":"2011","author":"CC Ferrari","year":"2011","unstructured":"Ferrari CC, Tarelli R. Parkinson\u2019s disease and systemic inflammation. Parkinsons Dis. 2011;2011:436813.","journal-title":"Parkinsons Dis"},{"key":"259_CR211","first-page":"247467","volume":"2011","author":"T Farooqui","year":"2011","unstructured":"Farooqui T, Farooqui AA. Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson\u2019s disease. Parkinsons Dis. 2011;2011:247467.","journal-title":"Parkinsons Dis"},{"key":"259_CR212","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbadis.2008.12.006","volume":"1792","author":"AH Tsang","year":"2009","unstructured":"Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkinson\u2019s disease. Biochim Biophys Acta. 2009;1792:643\u201350.","journal-title":"Biochim Biophys Acta"},{"key":"259_CR213","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1523\/JNEUROSCI.3732-10.2011","volume":"31","author":"HM Gao","year":"2011","unstructured":"Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci. 2011;31:1081\u201392.","journal-title":"J Neurosci"},{"key":"259_CR214","doi-asserted-by":"crossref","first-page":"172.28","DOI":"10.4049\/jimmunol.188.Supp.172.28","volume":"188","author":"EA Ko","year":"2012","unstructured":"Ko EA, Min HJ, Shin JS. Interaction of High Mobility Group Box-1 (HMGB1) with \u03b1-synuclein and its aggregation [abstract]. J Immunol. 2012;188:172.28.","journal-title":"J Immunol"},{"key":"259_CR215","first-page":"2735","volume":"15","author":"EK Lindersson","year":"2004","unstructured":"Lindersson EK, H\u00f8jrup P, Gai WP, Locker D, Martin D, Jensen PH. Alpha-synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport. 2004;15:2735\u20139.","journal-title":"Neuroreport"},{"key":"259_CR216","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/glia.22437","volume":"61","author":"L Fellner","year":"2013","unstructured":"Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, et al. Toll-like receptor 4 is required for \u03b1-synuclein dependent activation of microglia and astroglia. Glia. 2013;61:349\u201360.","journal-title":"Glia"},{"key":"259_CR217","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/ncomms2534","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, et al. Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.","journal-title":"Nat Commun"},{"key":"259_CR218","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","volume":"54","author":"AH Schapira","year":"1990","unstructured":"Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson\u2019s disease. J Neurochem. 1990;54:823\u20137.","journal-title":"J Neurochem"},{"key":"259_CR219","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/0006-291X(89)91141-8","volume":"163","author":"Y Mizuno","year":"1989","unstructured":"Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson\u2019s disease. Biochem Biophys Res Commun. 1989;163:1450\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"259_CR220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-510X(91)90311-T","volume":"104","author":"L Bindoff","year":"1991","unstructured":"Bindoff L, Birch-Machin M, Cartlidge N, Parker Jr W, Turnbull D. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson\u2019s disease. J Neurol Sci. 1991;104:203\u20138.","journal-title":"J Neurol Sci"},{"key":"259_CR221","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1212\/WNL.45.11.2097","volume":"45","author":"A Penn","year":"1995","unstructured":"Penn A, Roberts T, Hodder J, Allen P, Zhu G, Martin W. Generalized mitochondrial dysfunction in Parkinson\u2019s disease detected by magnetic resonance spectroscopy of muscle. Neurology. 1995;45:2097\u20139.","journal-title":"Neurology"},{"key":"259_CR222","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0022-510X(94)90248-8","volume":"125","author":"O Blin","year":"1994","unstructured":"Blin O, Desnuelle C, Rascol O, Borg M, Paul H, Azulay JP, et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson\u2019s disease and multiple system atrophy. J Neurol Sci. 1994;125:95\u2013101.","journal-title":"J Neurol Sci"},{"key":"259_CR223","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ana.410370604","volume":"37","author":"R Haas","year":"1995","unstructured":"Haas R, Nasirian F, Nakano K, Ward D, Pay M, Hill R, et al. Low platelet mitochondrial complex I and complex II\/III activity in early untreated Parkinson\u2019s disease. Ann Neurol. 1995;37:714\u201322.","journal-title":"Ann Neurol"},{"key":"259_CR224","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.410320612","volume":"32","author":"D Krige","year":"1992","unstructured":"Krige D, Carroll M, Cooper J, Marsden C, Schapira A. Platelet mitochondrial function in Parkinson\u2019s disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol. 1992;32:782\u20138.","journal-title":"Ann Neurol"},{"key":"259_CR225","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1523\/JNEUROSCI.0984-06.2006","volume":"26","author":"PM Keeney","year":"2006","unstructured":"Keeney PM, Xie J, Capaldi RA, Bennett Jr JP. Parkinson\u2019s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci. 2006;26:5256\u201364.","journal-title":"J Neurosci"},{"key":"259_CR226","doi-asserted-by":"crossref","first-page":"10756","DOI":"10.1523\/JNEUROSCI.23-34-10756.2003","volume":"23","author":"TB Sherer","year":"2003","unstructured":"Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson\u2019s disease. J Neurosci. 2003;23:10756\u201364.","journal-title":"J Neurosci"},{"key":"259_CR227","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/1531-8249(200011)48:5<774::AID-ANA11>3.0.CO;2-I","volume":"48","author":"M Rana","year":"2000","unstructured":"Rana M, de Coo I, Diaz F, Smeets H, Moraes CT. An out-of-frame cytochrome b gene deletion from a patient with parkinsonism is associated with impaired complex III assembly and an increase in free radical production. Ann Neurol. 2000;48:774\u201381.","journal-title":"Ann Neurol"},{"key":"259_CR228","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1097-2765(04)00124-8","volume":"13","author":"R Ac\u00edn-P\u00e9rez","year":"2004","unstructured":"Ac\u00edn-P\u00e9rez R, Bayona-Bafaluy MP, Fern\u00e1ndez-Silva P, Moreno-Loshuertos R, P\u00e9rez-Martos A, Bruno C, et al. Respiratory complex III is required to maintain complex I in mammalian mitochondria. Mol Cell. 2004;13:805\u201315.","journal-title":"Mol Cell"},{"key":"259_CR229","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ana.410420221","volume":"42","author":"CW Shults","year":"1997","unstructured":"Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II\/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997;42:261\u20134.","journal-title":"Ann Neurol"},{"key":"259_CR230","doi-asserted-by":"crossref","first-page":"a009274","DOI":"10.1101\/cshperspect.a009274","volume":"2","author":"M Niethammer","year":"2012","unstructured":"Niethammer M, Feigin A, Eidelberg D. Functional neuroimaging in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2:a009274.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"259_CR231","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1602\/neurorx.1.2.243","volume":"1","author":"D Brooks","year":"2004","unstructured":"Brooks D. Neuroimaging in Parkinson\u2019s disease. NeuroRx. 2004;1:243\u201354.","journal-title":"NeuroRx"},{"key":"259_CR232","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fnhum.2014.00063","volume":"8","author":"N Shao","year":"2014","unstructured":"Shao N, Yang J, Li J, Shang H. Voxelwise meta-analysis of gray matter anomalies in progressive supranuclear palsy and Parkinson\u2019s disease using anatomic likelihood estimation. Front Hum Neurosci. 2014;8:63.","journal-title":"Front Hum Neurosci"},{"key":"259_CR233","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.4103\/1673-5374.121625","volume":"8","author":"J Xia","year":"2013","unstructured":"Xia J, Miu J, Ding H, Wang X, Chen H, Wang J, et al. Changes of brain gray matter structure in Parkinson\u2019s disease patients with dementia. Neural Regen Res. 2013;8:1276\u201385.","journal-title":"Neural Regen Res"},{"key":"259_CR234","doi-asserted-by":"crossref","first-page":"e85595","DOI":"10.1371\/journal.pone.0085595","volume":"9","author":"I Rektorova","year":"2014","unstructured":"Rektorova I, Biundo R, Marecek R, Weis L, Aarsland D, Antonini A. Grey matter changes in cognitively impaired Parkinson\u2019s disease patients. PLos One. 2014;9:e85595.","journal-title":"PLos One"},{"key":"259_CR235","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3233\/JPD-130276","volume":"3","author":"U Ellfolk","year":"2013","unstructured":"Ellfolk U, Joutsa J, Rinne J, Parkkola R, Jokinen P, Karrasch M. Brain volumetric correlates of memory in early Parkinson\u2019s disease. J Parkinsons Dis. 2013;3:593\u2013601.","journal-title":"J Parkinsons Dis"},{"key":"259_CR236","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1212\/01.WNL.0000149510.41793.50","volume":"64","author":"A Nagano-Saito","year":"2005","unstructured":"Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JP, Evans AC, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology. 2005;64:224\u20139.","journal-title":"Neurology"},{"key":"259_CR237","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.parkreldis.2014.03.009","volume":"20","author":"H Lee","year":"2014","unstructured":"Lee H, Kwon K, Kim M, Jang J, Suh S, Koh S, et al. Subcortical grey matter changes in untreated, early stage Parkinson\u2019s disease without dementia. Parkinsonism Relat Disord. 2014;20:622\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"259_CR238","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1468-1331.2010.03010.x","volume":"17","author":"C Guevara","year":"2010","unstructured":"Guevara C, Blain C, Stahl D, Lythgoe D, Leigh P, Barker G. Quantitative magnetic resonance spectroscopic imaging in Parkinson\u2019s disease, progressive supranuclear palsy and multiple system atrophy. Eur J Neurol. 2010;17:1193\u2013202.","journal-title":"Eur J Neurol"},{"key":"259_CR239","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.jcbfm.9600192","volume":"26","author":"M Rango","year":"2005","unstructured":"Rango M, Bonifati C, Bresolin N. Parkinson\u2019s disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab. 2005;26:283\u201390.","journal-title":"J Cereb Blood Flow Metab"},{"key":"259_CR240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1531-8249(20010201)49:2<155::AID-ANA35>3.0.CO;2-9","volume":"49","author":"M Fukuda","year":"2001","unstructured":"Fukuda M, Mentis M, Ghilardi MF, Dhawan V, Antonini A, Hammerstad J, et al. Functional correlates of pallidal stimulation for Parkinson\u2019s disease. Ann Neurol. 2001;49:155\u201364.","journal-title":"Ann Neurol"},{"key":"259_CR241","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/brain\/124.8.1601","volume":"124","author":"M Fukuda","year":"2001","unstructured":"Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson\u2019s disease: a PET study of resting-state glucose metabolism. Brain. 2001;124:1601\u20139.","journal-title":"Brain"},{"key":"259_CR242","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.neuroimage.2006.09.003","volume":"34","author":"C Huang","year":"2007","unstructured":"Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson\u2019s disease. Neuroimage. 2007;34:714\u201323.","journal-title":"Neuroimage"},{"key":"259_CR243","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/mds.22444","volume":"24","author":"Y Hosokai","year":"2009","unstructured":"Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson\u2019s disease with and without mild cognitive impairment. Mov Disord. 2009;24:854\u201362.","journal-title":"Mov Disord"},{"key":"259_CR244","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1176\/appi.ajp.159.5.746","volume":"159","author":"MJ Mentis","year":"2002","unstructured":"Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson\u2019s disease. Am J Psychiatry. 2002;159:746\u201354.","journal-title":"Am J Psychiatry"},{"key":"259_CR245","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1212\/01.wnl.0000304050.05332.9c","volume":"70","author":"C Huang","year":"2008","unstructured":"Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008;70:1470\u20137.","journal-title":"Neurology"},{"key":"259_CR246","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00429-010-0246-0","volume":"214","author":"P Borghammer","year":"2010","unstructured":"Borghammer P, Chakravarty M, Jonsdottir K, Sato N, Matsuda H, Ito K, et al. Cortical hypometabolism and hypoperfusion in Parkinson\u2019s disease is extensive: probably even at early disease stages. Brain Struct Funct. 2010;214:303\u201317.","journal-title":"Brain Struct Funct"},{"key":"259_CR247","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/jnr.490270417","volume":"27","author":"RF Peppard","year":"1990","unstructured":"Peppard RF, Martin WR, Clark CM, Carr GD, McGeer PL, Calne DB. Cortical glucose metabolism in Parkinson\u2019s and Alzheimer\u2019s disease. J Neurosci Res. 1990;27:561\u20138.","journal-title":"J Neurosci Res"},{"key":"259_CR248","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1468-1331.2007.01977.x","volume":"14","author":"SW Yong","year":"2007","unstructured":"Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson\u2019s disease, Parkinson\u2019s disease dementia and dementia with Lewy bodies. Eur J Neurol. 2007;14:1357\u201362.","journal-title":"Eur J Neurol"},{"key":"259_CR249","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.neuroimage.2011.10.033","volume":"59","author":"M Fern\u00e1ndez-Seara","year":"2012","unstructured":"Fern\u00e1ndez-Seara M, Mengual E, Vidorreta M, Aznarez-Sanado M, Loayza F, Villagra F, et al. Cortical hypoperfusion in Parkinson\u2019s disease assessed using arterial spin labeled perfusion MRI. Neuroimage. 2012;59:2743\u201350.","journal-title":"Neuroimage"},{"key":"259_CR250","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jmri.22515","volume":"33","author":"K Kamagata","year":"2011","unstructured":"Kamagata K, Motoi Y, Hori M, Suzuki M, Nakanishi A, Shimoji K, et al. Posterior hypoperfusion in Parkinson\u2019s disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging. 2011;33:803\u20137.","journal-title":"J Magn Reson Imaging"},{"key":"259_CR251","first-page":"12","volume":"1","author":"H Marin","year":"2004","unstructured":"Marin H, Menza MA. Specific treatment of residual fatigue in depressed patients. Psychiatry (Edgmont). 2004;1:12\u20138.","journal-title":"Psychiatry (Edgmont)"},{"key":"259_CR252","first-page":"185","volume":"6","author":"H Marin","year":"2005","unstructured":"Marin H, Menza MA. The management of fatigue in depressed patients. Essent Psychopharmacol. 2005;6:185\u201392.","journal-title":"Essent Psychopharmacol"},{"key":"259_CR253","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00406-002-0381-6","volume":"252","author":"J Angst","year":"2002","unstructured":"Angst J, Gamma A, Gastpar M, L\u00e9pine JP, Mendlewicz J, Tylee A, et al. Gender differences in depression. Epidemiological findings from the European DEPRES I and II studies. Eur Arch Psychiatry Clin Neurosci. 2002;252:201\u20139.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"259_CR254","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2003.04.070","volume":"21","author":"GR Morrow","year":"2003","unstructured":"Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PL, Flynn PJ, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003;21:4635\u201341.","journal-title":"J Clin Oncol"},{"key":"259_CR255","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4088\/JCP.v64n0811","volume":"64","author":"AJ Hartz","year":"2003","unstructured":"Hartz AJ, Bentler SE, Brake KA, Kelly MW. The effectiveness of citalopram for idiopathic chronic fatigue. J Clin Psychiatry. 2003;64:927\u201335.","journal-title":"J Clin Psychiatry"},{"key":"259_CR256","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004714-200204000-00006","volume":"22","author":"M Fava","year":"2002","unstructured":"Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder. J Clin Psychopharmacol. 2002;22:137\u201347.","journal-title":"J Clin Psychopharmacol"},{"key":"259_CR257","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1192\/bjp.172.6.485","volume":"172","author":"AJ Wearden","year":"1998","unstructured":"Wearden AJ, Morriss RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, et al. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry. 1998;172:485\u201390.","journal-title":"Br J Psychiatry"},{"key":"259_CR258","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0029-1202263","volume":"42","author":"C Song","year":"2009","unstructured":"Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry. 2009;42:182\u20138.","journal-title":"Pharmacopsychiatry"},{"key":"259_CR259","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.neubiorev.2011.12.005","volume":"36","author":"B Leonard","year":"2012","unstructured":"Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012;36:764\u201385.","journal-title":"Neurosci Biobehav Rev"},{"key":"259_CR260","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.pnpbp.2010.06.014","volume":"35","author":"M Maes","year":"2011","unstructured":"Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:664\u201375.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"259_CR261","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2009.09.009","volume":"24","author":"AH Miller","year":"2010","unstructured":"Miller AH. Depression and immunity: a role for T cells? Brain Behav Immun. 2010;24:1\u20138.","journal-title":"Brain Behav Immun"},{"key":"259_CR262","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1742-2094-8-151","volume":"8","author":"I G\u00e1rate","year":"2011","unstructured":"G\u00e1rate I, Garc\u00eda-Bueno B, Madrigal JL, Bravo L, Berrocoso E, Caso JR, et al. Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. J Neuroinflammation. 2011;8:151.","journal-title":"J Neuroinflammation"},{"key":"259_CR263","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpsychires.2014.01.021","volume":"53","author":"GN Pandey","year":"2014","unstructured":"Pandey GN, Rizavi HS, Ren X, Bhaumik R, Dwivedi Y. Toll-like receptors in the depressed and suicide brain. J Psychiatr Res. 2014;53:62\u20138.","journal-title":"J Psychiatr Res"},{"key":"259_CR264","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.pnpbp.2010.07.030","volume":"35","author":"A Gardner","year":"2011","unstructured":"Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:730\u201343.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"259_CR265","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1176\/appi.ajp.2012.11071105","volume":"169","author":"JP Hamilton","year":"2012","unstructured":"Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH. Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data. Am J Psychiatry. 2012;169:693\u2013703.","journal-title":"Am J Psychiatry"},{"key":"259_CR266","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archgenpsychiatry.2011.60","volume":"68","author":"MJ Kempton","year":"2011","unstructured":"Kempton MJ, Salvador Z, Munaf\u00f2 MR, Geddes JR, Simmons A, Frangou S, et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry. 2011;68:675\u201390.","journal-title":"Arch Gen Psychiatry"},{"key":"259_CR267","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/mp.2012.150","volume":"18","author":"D Arnone","year":"2012","unstructured":"Arnone D, McKie S, Elliott R, Juhasz G, Thomas E, Downey D, et al. State-dependent changes in hippocampal grey matter in depression. Mol Psychiatry. 2012;18:1265\u201372.","journal-title":"Mol Psychiatry"},{"key":"259_CR268","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.nicl.2013.08.016","volume":"3","author":"S Grieve","year":"2013","unstructured":"Grieve S, Korgaonkar M, Koslow S, Gordon E, Williams L. Widespread reductions in gray matter volume in depression. Neuroimage Clin. 2013;3:332\u20139.","journal-title":"Neuroimage Clin"},{"key":"259_CR269","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jad.2011.03.049","volume":"138","author":"E Bora","year":"2012","unstructured":"Bora E, Fornito A, Pantelis C, Y\u00fccel M. Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord. 2012;138:9\u201318.","journal-title":"J Affect Disord"},{"key":"259_CR270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pnpbp.2011.09.014","volume":"36","author":"M Du","year":"2012","unstructured":"Du M, Wu Q, Yue Q, Li J, Liao Y, Kuang W, et al. Voxelwise meta-analysis of gray matter reduction in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:11\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"259_CR271","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejrad.2010.04.006","volume":"80","author":"J Peng","year":"2011","unstructured":"Peng J, Liu J, Nie B, Li Y, Shan B, Wang G, et al. Cerebral and cerebellar gray matter reduction in first-episode patients with major depressive disorder: a voxel-based morphometry study. Eur J Radiol. 2011;80:395\u20139.","journal-title":"Eur J Radiol"},{"key":"259_CR272","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0924-9338(11)72666-9","volume":"26","author":"S Walther","year":"2011","unstructured":"Walther S, H\u00f6fle O, Federspiel A, Horn H, Strik W, Muller T. P02-365-Frontotemporal resting state hypoperfusion in patients with major depression-a study using arterial spin labeling. Eur Psychiatry. 2011;26:961.","journal-title":"Eur Psychiatry"},{"key":"259_CR273","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jaac.2013.07.008","volume":"52","author":"T Ho","year":"2013","unstructured":"Ho T, Wu J, Shin D, Liu T, Tapert S, Yang G, et al. Altered cerebral perfusion in executive, affective, and motor networks during adolescent depression. J Am Acad Child Adolesc Psychiatry. 2013;52:1076\u201391.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"259_CR274","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pscychresns.2013.11.002","volume":"221","author":"S Terada","year":"2014","unstructured":"Terada S, Oshima E, Sato S, Ikeda C, Nagao S, Hayashi S, et al. Depressive symptoms and regional cerebral blood flow in Alzheimer\u2019s disease. Psychiatry Res. 2014;221:86\u201391.","journal-title":"Psychiatry Res"},{"key":"259_CR275","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jad.2014.04.032","volume":"165","author":"M Ota","year":"2014","unstructured":"Ota M, Noda T, Sato N, Hattori K, Teraishi T, Hori H, et al. Characteristic distributions of regional cerebral blood flow changes in major depressive disorder patients: a pseudo-continuous arterial spin labeling (pCASL) study. J Affect Disord. 2014;165:59\u201363.","journal-title":"J Affect Disord"},{"key":"259_CR276","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1176\/ajp.147.10.1313","volume":"147","author":"J Martinot","year":"1990","unstructured":"Martinot J, Hardy P, Feline A, Huret J, Mazoyer B, Attar-Levy D, et al. Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am J Psychiatry. 1990;147:1313\u20137.","journal-title":"Am J Psychiatry"},{"key":"259_CR277","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pnpbp.2008.11.014","volume":"33","author":"T Hosokawa","year":"2009","unstructured":"Hosokawa T, Momose T, Kasai K. Brain glucose metabolism difference between bipolar and unipolar mood disorders in depressed and euthymic states. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:243\u201350.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"259_CR278","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1212\/WNL.50.2.380","volume":"50","author":"N Hirono","year":"1998","unstructured":"Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, et al. Frontal lobe hypometabolism and depression in Alzheimer\u2019s disease. Neurology. 1998;50:380\u20133.","journal-title":"Neurology"},{"key":"259_CR279","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1742-2094-8-94","volume":"8","author":"J Steiner","year":"2011","unstructured":"Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:94.","journal-title":"J Neuroinflammation"},{"key":"259_CR280","first-page":"1450","volume":"17","author":"LB Krupp","year":"1990","unstructured":"Krupp LB, LaRocca NG, Muir J, Steinberg AD. A study of fatigue in systemic lupus erythematosus. J Rheumatol. 1990;17:1450\u20132.","journal-title":"J Rheumatol"},{"key":"259_CR281","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121\u20133.","journal-title":"Arch Neurol"},{"key":"259_CR282","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1212\/WNL.39.1.144","volume":"39","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, Larocca NC, Luft BJ, Halpern JJ. Comparison of neurologic and psychologic findings in patients with Lyme disease and chronic fatigue syndrome. Neurology. 1989;39:144.","journal-title":"Neurology"},{"key":"259_CR283","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.pmrj.2010.03.026","volume":"2","author":"R Ramsey-Goldman","year":"2010","unstructured":"Ramsey-Goldman R, Rothrock N. Fatigue in systemic lupus erythematosus and rheumatoid arthritis. PM R. 2010;2:384\u201392.","journal-title":"PM R"},{"key":"259_CR284","first-page":"1282","volume":"33","author":"D Da Costa","year":"2006","unstructured":"Da Costa D, Dritsa M, Bernatsky S, Pineau C, M\u00e9nard HA, Dasgupta K, et al. Dimensions of fatigue in systemic lupus erythematosus: relationship to disease status and behavioral and psychosocial factors. J Rheumatol. 2006;33:1282\u20138.","journal-title":"J Rheumatol"},{"key":"259_CR285","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1191\/096120398678919813","volume":"7","author":"PR Fortin","year":"1998","unstructured":"Fortin PR, Abrahamowicz M, Neville C, du Berger R, Fraenkel L, Clarke AE, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus. 1998;7:101\u20137.","journal-title":"Lupus"},{"key":"259_CR286","first-page":"525","volume":"28","author":"C Wang","year":"2001","unstructured":"Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol. 2001;28:525\u201332.","journal-title":"J Rheumatol"},{"key":"259_CR287","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/art.24347","volume":"61","author":"AM Al Dhanhani","year":"2009","unstructured":"Al Dhanhani AM, Gignac MA, Su J, Fortin PR. Work disability in systemic lupus erythematosus. Arthritis Rheum. 2009;61:378\u201385.","journal-title":"Arthritis Rheum"},{"key":"259_CR288","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.24063","volume":"59","author":"P Panopalis","year":"2008","unstructured":"Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 2008;59:1788\u201395.","journal-title":"Arthritis Rheum"},{"key":"259_CR289","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0168-8278(90)90046-T","volume":"10","author":"B Campillo","year":"1990","unstructured":"Campillo B, Fouet P, Bonnet JC, Atlan G. Submaximal oxygen consumption in liver cirrhosis. Evidence of severe functional aerobic impairment. J Hepatol. 1990;10:163\u20137.","journal-title":"J Hepatol"},{"key":"259_CR290","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/art.10926","volume":"49","author":"RE Keyser","year":"2003","unstructured":"Keyser RE, Rus V, Cade WT, Kalappa N, Flores RH, Handwerger BS. Evidence for aerobic insufficiency in women with systemic Lupus erythematosus. Arthritis Rheum. 2003;49:16\u201322.","journal-title":"Arthritis Rheum"},{"key":"259_CR291","first-page":"23","volume":"32","author":"D Zdrenghea","year":"1994","unstructured":"Zdrenghea D, Giurgea N, Predescu D, Timi\u015f D, Icu\u015fc\u0103 G. Exercise testing in patients with valvular diseases. Rom J Intern Med. 1994;32:23\u20138.","journal-title":"Rom J Intern Med"},{"key":"259_CR292","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/rheumatology\/32.7.633","volume":"32","author":"AJ Wysenbeek","year":"1993","unstructured":"Wysenbeek AJ, Leibovici L, Weinberger A, Guedj D. Fatigue in systemic lupus erythematosus. Prevalence and relation to disease expression. Br J Rheumatol. 1993;32:633\u20135.","journal-title":"Br J Rheumatol"},{"key":"259_CR293","doi-asserted-by":"crossref","unstructured":"Zonana\u2010Nacach A, Roseman JM, McGwin G, Friedman AW, Baethge BA, Reveille JD. Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5\u00a0years of criteria diagnosis. Lupus. 2000; 9:101\u2013109.","DOI":"10.1191\/096120300678828046"},{"key":"259_CR294","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3917","volume":"14","author":"V Marian","year":"2012","unstructured":"Marian V, Anolik JH. Treatment targets in systemic lupus erythematosus: biology and clinical perspective. Arthritis Res Ther. 2012;14:S3.","journal-title":"Arthritis Res Ther"},{"key":"259_CR295","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00393-008-0303-8","volume":"67","author":"M Aringer","year":"2008","unstructured":"Aringer M, Feierl E, Smolen J. Cytokine blockade-a promising therapeutic option in SLE. Z Rheumatol. 2008;67:315\u20137 [in German].","journal-title":"Z Rheumatol"},{"key":"259_CR296","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cyto.2006.07.023","volume":"35","author":"A Sabry","year":"2006","unstructured":"Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan K, George S, et al. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine. 2006;35:148\u201353.","journal-title":"Cytokine"},{"key":"259_CR297","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/ar3349","volume":"13","author":"N Jacob","year":"2011","unstructured":"Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011;13:228.","journal-title":"Arthritis Res Ther"},{"key":"259_CR298","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1191\/0961203303lu1024oa","volume":"13","author":"M Aringer","year":"2004","unstructured":"Aringer M, Smolen J. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus. 2004;13:344\u20137.","journal-title":"Lupus"},{"key":"259_CR299","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0268-960X(93)90006-P","volume":"7","author":"DM Keeling","year":"1993","unstructured":"Keeling DM, Isenberg DA. Haematological manifestations of systemic lupus erythematosus. Blood Rev. 1993;7:199\u2013207.","journal-title":"Blood Rev"},{"key":"259_CR300","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/art.27442","volume":"62","author":"G Wang","year":"2010","unstructured":"Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum. 2010;62:2064\u201372.","journal-title":"Arthritis Rheum"},{"key":"259_CR301","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.autrev.2008.07.046","volume":"8","author":"WU Kim","year":"2009","unstructured":"Kim WU, Sreih A, Bucala R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev. 2009;8:204\u20138.","journal-title":"Autoimmun Rev"},{"key":"259_CR302","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00281-006-0034-3","volume":"28","author":"AH Rahman","year":"2006","unstructured":"Rahman AH, Eisenberg RA. The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol. 2006;28:131\u201343.","journal-title":"Springer Semin Immunopathol"},{"key":"259_CR303","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1750-1172-8-2","volume":"8","author":"N Tiffin","year":"2013","unstructured":"Tiffin N, Adeyemo A, Okpechi I. A diverse array of genetic factors contribute to the pathogenesis of systemic lupus erythematosus. Orphanet J Rare Dis. 2013;8:2.","journal-title":"Orphanet J Rare Dis"},{"key":"259_CR304","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2050-7771-1-20","volume":"1","author":"T Dhaouadi","year":"2013","unstructured":"Dhaouadi T, Sfar I, Haouami Y, Abdelmoula L, Turki S, Hassine LB, et al. Polymorphisms of Toll-like receptor-4 and CD14 in systemic lupus erythematosus and rheumatoid arthritis. Biomark Res. 2013;1:20.","journal-title":"Biomark Res"},{"key":"259_CR305","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12035-013-8553-0","volume":"49","author":"G Morris","year":"2014","unstructured":"Morris G, Berk M, Galecki P, Maes M. The emerging role of autoimmunity in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/cfs). Mol Neurobiol. 2014;49:741\u201356.","journal-title":"Mol Neurobiol"},{"key":"259_CR306","first-page":"1873","volume":"33","author":"L Harel","year":"2006","unstructured":"Harel L, Sandborg C, Lee T, von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol. 2006;33:1873\u20137.","journal-title":"J Rheumatol"},{"key":"259_CR307","doi-asserted-by":"crossref","first-page":"9302","DOI":"10.1371\/journal.pone.0009302","volume":"5","author":"R Jung","year":"2010","unstructured":"Jung R, Segall J, Grazioplene R, Qualls C, Sibbitt Jr W, Roldan C. Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus. PLos One. 2010;5:9302.","journal-title":"PLos One"},{"key":"259_CR308","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/art.24937","volume":"60","author":"J Birnbaum","year":"2009","unstructured":"Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009;60:3378\u201387.","journal-title":"Arthritis Rheum"},{"key":"259_CR309","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/0961203307084723","volume":"16","author":"S Appenzeller","year":"2007","unstructured":"Appenzeller S, Li L, Costallat L, Cendes F. Neurometabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus. Lupus. 2007;16:963\u201371.","journal-title":"Lupus"},{"key":"259_CR310","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.21483","volume":"64","author":"S Appenzeller","year":"2008","unstructured":"Appenzeller S, Vasconcelos Faria A, Li L, Costallat L, Cendes F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol. 2008;64:635\u201343.","journal-title":"Ann Neurol"},{"key":"259_CR311","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/ard.2004.026773","volume":"64","author":"G Castellino","year":"2005","unstructured":"Castellino G, Govoni M, Padovan M, Colamussi P, Borrelli M, Trotta F. Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up. Ann Rheum Dis. 2005;64:1022\u20137.","journal-title":"Ann Rheum Dis"},{"key":"259_CR312","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/jnnp.2007.120626","volume":"79","author":"E Harboe","year":"2008","unstructured":"Harboe E, Greve O, Beyer M, Goransson L, Tjensvoll A, Maroni S, et al. Fatigue is associated with cerebral white matter hyperintensities in patients with systemic lupus erythematosus. J Neurol Neurosurg Psychiatry. 2008;79:199\u2013201.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"259_CR313","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1741-7015-11-91","volume":"11","author":"T Gono","year":"2013","unstructured":"Gono T, Kawaguchi Y, Yamanaka H. Discoveries in the pathophysiology of neuropsychiatric lupus erythematosus: consequences for therapy. BMC Med. 2013;11:91.","journal-title":"BMC Med"},{"key":"259_CR314","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1002\/art.30616","volume":"63","author":"T Gono","year":"2011","unstructured":"Gono T, Takarada T, Fukumori R, Kawaguchi Y, Kaneko H, Hanaoka M, et al. NR2-reactive antibody decreases cell viability through augmentation of Ca(2+) influx in systemic lupus erythematosus. Arthritis Rheum. 2011;63:3952\u20139.","journal-title":"Arthritis Rheum"},{"key":"259_CR315","doi-asserted-by":"crossref","first-page":"19854","DOI":"10.1073\/pnas.0608397104","volume":"103","author":"C Kowal","year":"2006","unstructured":"Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A. 2006;103:19854\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"259_CR316","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/nm1101-1189","volume":"7","author":"LA DeGiorgio","year":"2001","unstructured":"DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001;7:1189\u201393.","journal-title":"Nat Med"},{"key":"259_CR317","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/ard.57.5.291","volume":"57","author":"PJ Barendregt","year":"1998","unstructured":"Barendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH, Boomsma F, et al. Fatigue in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 1998;57:291\u20135.","journal-title":"Ann Rheum Dis"},{"key":"259_CR318","first-page":"125","volume":"40","author":"HM Markusse","year":"1992","unstructured":"Markusse HM, Oudkerk M, Vroom TM, Breedveld FC. Primary Sj\u00f6gren\u2019s syndrome: clinical spectrum and mode of presentation based on an analysis of 50 patients selected from a department of rheumatology. Neth J Med. 1992;40:125\u201334.","journal-title":"Neth J Med"},{"key":"259_CR319","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/rheumatology\/keq009","volume":"49","author":"WF Ng","year":"2010","unstructured":"Ng WF, Bowman SJ. Primary Sjogren\u2019s syndrome: too dry and too tired. Rheumatology (Oxford). 2010;49:844\u201353.","journal-title":"Rheumatology (Oxford)"},{"key":"259_CR320","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/ard.59.11.875","volume":"59","author":"I Giles","year":"2000","unstructured":"Giles I, Isenberg D. Fatigue in primary Sj\u00f6gren's syndrome: is there a link with the fibromyalgia syndrome? Ann Rheum Dis. 2000;59:875\u20138.","journal-title":"Ann Rheum Dis"},{"key":"259_CR321","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.61.3.284","volume":"61","author":"HI Bax","year":"2002","unstructured":"Bax HI, Vriesendorp TM, Kallenberg CG, Kalk WW. Fatigue and immune activity in Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2002;61:284.","journal-title":"Ann Rheum Dis"},{"key":"259_CR322","first-page":"313","volume":"19","author":"EK Tensing","year":"2001","unstructured":"Tensing EK, Solovieva SA, Tervahartiala T, Nordstr\u00f6m DC, Laine M, Niissalo S, et al. Fatigue and health profile in sicca syndrome of Sj\u00f6gren\u2019s and non-Sj\u00f6gren\u2019s syndrome origin. Clin Exp Rheumatol. 2001;19:313\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"259_CR323","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar3487","volume":"13","author":"K Haldorsen","year":"2011","unstructured":"Haldorsen K, Bjelland I, Bolstad AI, Jonsson R, Brun JG. A five-year prospective study of fatigue in primary Sj\u00f6gren\u2019s syndrome. Arthritis Res Ther. 2011;13:R167.","journal-title":"Arthritis Res Ther"},{"key":"259_CR324","doi-asserted-by":"crossref","first-page":"30123","DOI":"10.1371\/journal.pone.0030123","volume":"7","author":"K Norheim","year":"2012","unstructured":"Norheim K, Harboe E, Goransson L, Omdal R. Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren\u2019s syndrome\u2013a double blind, randomised clinical trial. PLos One. 2012;7:30123.","journal-title":"PLos One"},{"key":"259_CR325","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/ar3348","volume":"13","author":"P Youinou","year":"2011","unstructured":"Youinou P, Pers J. Disturbance of cytokine networks in Sj\u00f6grens syndrome. Arthritis Res Ther. 2011;13:227.","journal-title":"Arthritis Res Ther"},{"key":"259_CR326","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.0300-9475.2004.01432.x","volume":"59","author":"P Szodoray","year":"2004","unstructured":"Szodoray P, Alex P, Brun J, Centola M, Jonsson R. Circulating cytokines in primary Sj\u00f6gren\u2019s syndrome determined by a multiplex cytokine array system. Scand J Immunol. 2004;59:592\u20139.","journal-title":"Scand J Immunol"},{"key":"259_CR327","first-page":"89","volume":"25","author":"E Hagiwara","year":"1998","unstructured":"Hagiwara E, Pando J, Ishigatsubo Y, Klinman D. Altered frequency of type 1 cytokine secreting cells in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome. J Rheumatol. 1998;25:89\u201393.","journal-title":"J Rheumatol"},{"key":"259_CR328","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2353\/ajpath.2009.090319","volume":"175","author":"G Katsifis","year":"2009","unstructured":"Katsifis G, Rekka S, Moutsopoulos N, Pillemer S, Wahl S. Systemic and local interleukin-17 and linked cytokines associated with Sj\u00f6gren\u2019s syndrome immunopathogenesis. Am J Pathol. 2009;175:1167\u201377.","journal-title":"Am J Pathol"},{"key":"259_CR329","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/ar3318","volume":"13","author":"HZ Low","year":"2011","unstructured":"Low HZ, Witte T. Aspects of innate immunity in Sj\u00f6gren\u2019s syndrome. Arthritis Res Ther. 2011;13:218.","journal-title":"Arthritis Res Ther"},{"key":"259_CR330","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jaut.2010.06.012","volume":"35","author":"CP Mavragani","year":"2010","unstructured":"Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren\u2019s syndrome. J Autoimmun. 2010;35:225\u201331.","journal-title":"J Autoimmun"},{"key":"259_CR331","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaut.2012.01.004","volume":"39","author":"YT Konttinen","year":"2012","unstructured":"Konttinen YT, Fuellen G, Bing Y, Porola P, Stegaev V, Trokovic N, et al. Sex steroids in Sj\u00f6gren\u2019s syndrome. J Autoimmun. 2012;39:49\u201356.","journal-title":"J Autoimmun"},{"key":"259_CR332","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2174\/138920112802273209","volume":"13","author":"M Bombardieri","year":"2012","unstructured":"Bombardieri M, Pitzalis C. Ectopic lymphoid neogenesis and lymphoid chemokines in Sjogren\u2019s syndrome: at the interplay between chronic inflammation, autoimmunity and lymphomagenesis. Curr Pharm Biotechnol. 2012;13:1989\u201396.","journal-title":"Curr Pharm Biotechnol"},{"key":"259_CR333","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1167\/iovs.12-10325","volume":"54","author":"TH Wakamatsu","year":"2013","unstructured":"Wakamatsu TH, Dogru M, Matsumoto Y, Kojima T, Kaido M, Ibrahim OM, et al. Evaluation of lipid oxidative stress status in Sj\u00f6gren syndrome patients. Invest Ophthalmol Vis Sci. 2013;54:201\u201310.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"259_CR334","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1093\/brain\/awh605","volume":"128","author":"K Mori","year":"2005","unstructured":"Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sj\u00f6gren\u2019s syndrome-associated neuropathy. Brain. 2005;128:2518\u201334.","journal-title":"Brain"},{"key":"259_CR335","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s004150170135","volume":"248","author":"C Lafitte","year":"2001","unstructured":"Lafitte C, Amoura Z, Cacoub P, Pradat-Diehl P, Picq C, Salachas F, et al. Neurological complications of primary Sj\u00f6gren\u2019s syndrome. J Neurol. 2001;248:577\u201384.","journal-title":"J Neurol"},{"key":"259_CR336","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2003.019497","volume":"63","author":"FC Soliotis","year":"2004","unstructured":"Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in Sjogren\u2019s syndrome. Ann Rheum Dis. 2004;63:616\u201320.","journal-title":"Ann Rheum Dis"},{"key":"259_CR337","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/03009749209095089","volume":"21","author":"R Manthorpe","year":"1992","unstructured":"Manthorpe R, Manthorpe T, Sj\u00f6berg S. Magnetic resonance imaging of the brain in patients with primary Sj\u00f6gren\u2019s syndrome. Scand J Rheumatol. 1992;21:148\u20139.","journal-title":"Scand J Rheumatol"},{"key":"259_CR338","doi-asserted-by":"crossref","first-page":"815","DOI":"10.7326\/0003-4819-108-6-815","volume":"108","author":"EL Alexander","year":"1988","unstructured":"Alexander EL, Beall SS, Gordon B, Selnes OA, Yannakakis GD, Patronas N, et al. Magnetic resonance imaging of cerebral lesions in patients with the Sj\u00f6gren syndrome. Ann Intern Med. 1988;108:815\u201323.","journal-title":"Ann Intern Med"},{"key":"259_CR339","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/keq111","volume":"49","author":"A Massara","year":"2010","unstructured":"Massara A, Bonazza S, Castellino G, Caniatti L, Trotta F, Borrelli M, et al. Central nervous system involvement in Sj\u00f6gren\u2019s syndrome: unusual, but not unremarkable\u2013clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology. 2010;49:1540\u20139.","journal-title":"Rheumatology"},{"key":"259_CR340","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/rheumatology\/keq070","volume":"49","author":"B Segal","year":"2010","unstructured":"Segal B, Mueller B, Zhu X, Prosser R, Pogatchnik B, Holker E, et al. Disruption of brain white matter microstructure in primary Sj\u00f6gren\u2019s syndrome: evidence from diffusion tensor imaging. Rheumatology. 2010;49:1530\u20139.","journal-title":"Rheumatology"},{"key":"259_CR341","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF00588375","volume":"35","author":"L Pierot","year":"1993","unstructured":"Pierot L, Sauve C, Leger J, Martin N, Koeger A, Wechsler B, et al. Asymptomatic cerebral involvement in Sj\u00f6gren\u2019s syndrome: MRI findings of 15 cases. Neuroradiology. 1993;35:378\u201380.","journal-title":"Neuroradiology"},{"key":"259_CR342","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2214\/AJR.10.5984","volume":"197","author":"L Tzarouchi","year":"2011","unstructured":"Tzarouchi L, Tsifetaki N, Konitsiotis S, Zikou A, Astrakas L, Drosos A, et al. CNS involvement in primary Sjogren Syndrome: assessment of gray and white matter changes with MRI and voxel-based morphometry. AJR Am J Roentgenol. 2011;197:1207\u201312.","journal-title":"AJR Am J Roentgenol"},{"key":"259_CR343","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/ene.12486","volume":"21","author":"M Lauvsnes","year":"2014","unstructured":"Lauvsnes M, Beyer M, Appenzeller S, Greve O, Harboe E, Goransson L, et al. Loss of cerebral white matter in primary Sj\u00f6gren\u2019s syndrome: a controlled volumetric magnetic resonance imaging study. Eur J Neurol. 2014;21:1324\u20139.","journal-title":"Eur J Neurol"},{"key":"259_CR344","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/rheumatology\/ken399","volume":"48","author":"H Repping-Wuts","year":"2009","unstructured":"Repping-Wuts H, van Riel P, van Achterberg T. Fatigue in patients with rheumatoid arthritis: what is known and what is needed. Rheumatology (Oxford). 2009;48:207\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"259_CR345","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2702.2007.02082.x","volume":"16","author":"H Repping-Wuts","year":"2007","unstructured":"Repping-Wuts H, Fransen J, van Achterberg T, Bleijenberg G, van Riel P. Persistent severe fatigue in patients with rheumatoid arthritis. J Clin Nurs. 2007;16:377\u201383.","journal-title":"J Clin Nurs"},{"key":"259_CR346","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijnurstu.2007.06.007","volume":"45","author":"H Repping-Wuts","year":"2008","unstructured":"Repping-Wuts H, Uitterhoeve R, van Riel P, van Achterberg T. Fatigue as experienced by patients with rheumatoid arthritis (RA): a qualitative study. Int J Nurs Stud. 2008;45:995\u20131002.","journal-title":"Int J Nurs Stud"},{"key":"259_CR347","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/art.21450","volume":"53","author":"S Hewlett","year":"2005","unstructured":"Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients\u2019 perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum. 2005;53:697\u2013702.","journal-title":"Arthritis Rheum"},{"key":"259_CR348","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/rheumatology\/kel021","volume":"45","author":"LC Pollard","year":"2006","unstructured":"Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford). 2006;45:885\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"259_CR349","first-page":"44","volume":"6","author":"M Sariyildiz","year":"2014","unstructured":"Sariyildiz M, Batmaz I, Bozkurt M, Bez Y, Cetincakmak M, Yazmalar L, et al. Sleep quality in rheumatoid arthritis: relationship between the disease severity, depression, functional status and the quality of life. J Clin Med Res. 2014;6:44.","journal-title":"J Clin Med Res"},{"key":"259_CR350","doi-asserted-by":"crossref","first-page":"63","DOI":"10.46497\/tjr.2010.09","volume":"25","author":"Y Turan","year":"2010","unstructured":"Turan Y, Kocaa\u011fa Z, Ko\u00e7yi\u011fit H, G\u00fcrgan A, Bayram KB, \u0130pek S. Correlation of fatigue with clinical parameters and quality of life in rheumatoid arthritis. Arch Rheumatol. 2010;25:63\u20137.","journal-title":"Arch Rheumatol"},{"key":"259_CR351","doi-asserted-by":"crossref","first-page":"327","DOI":"10.18388\/abp.2010_2412","volume":"57","author":"S Tukaj","year":"2010","unstructured":"Tukaj S, Kotlarz A, Jozwik A, Smolenska Z, Bryl E, Witkowski J, et al. Cytokines of the Th1 and Th2 type in sera of rheumatoid arthritis patients; correlations with anti-Hsp40 immune response and diagnostic markers. Acta Biochim Pol. 2010;57:327\u201332.","journal-title":"Acta Biochim Pol"},{"key":"259_CR352","first-page":"584","volume":"25","author":"P Alex","year":"2007","unstructured":"Alex P, Szodoray P, Knowlton N, Dozmorov I, Turner M, Frank M, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:584\u201392.","journal-title":"Clin Exp Rheumatol"},{"key":"259_CR353","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/ar3431","volume":"13","author":"D Chen","year":"2011","unstructured":"Chen D, Chen Y, Chen H, Hsieh C, Lin C, Lan J. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther. 2011;13:R126.","journal-title":"Arthritis Res Ther"},{"key":"259_CR354","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-065X.2008.00626.x","volume":"223","author":"M Feldmann","year":"2008","unstructured":"Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008;223:7\u201319.","journal-title":"Immunol Rev"},{"key":"259_CR355","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907\u201315.","journal-title":"N Engl J Med"},{"key":"259_CR356","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1007\/s00296-011-2143-0","volume":"32","author":"K Liepe","year":"2012","unstructured":"Liepe K. Efficacy of radiosynovectomy in rheumatoid arthritis. Rheumatol Int. 2012;32:3219\u201324.","journal-title":"Rheumatol Int"},{"key":"259_CR357","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/art.21838","volume":"55","author":"LW Moreland","year":"2006","unstructured":"Moreland LW, Genovese MC, Sato R, Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum. 2006;55:287\u201393.","journal-title":"Arthritis Rheum"},{"key":"259_CR358","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35\u201345.","journal-title":"Arthritis Rheum"},{"key":"259_CR359","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/rheumatology\/ker257","volume":"51","author":"F Goh","year":"2011","unstructured":"Goh F, Midwood K. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology. 2011;51:7\u201323.","journal-title":"Rheumatology"},{"key":"259_CR360","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11926-009-0051-z","volume":"11","author":"Q Huang","year":"2009","unstructured":"Huang Q, Pope R. The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep. 2009;11:357\u201364.","journal-title":"Curr Rheumatol Rep"},{"key":"259_CR361","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-59745-541-1_20","volume":"517","author":"F Brentano","year":"2009","unstructured":"Brentano F, Kyburz D, Gay S. Toll-like receptors and rheumatoid arthritis. Methods Mol Biol. 2009;517:329\u201343.","journal-title":"Methods Mol Biol"},{"key":"259_CR362","doi-asserted-by":"crossref","unstructured":"Szabo-Taylor K, Nagy G, Eggleton P, Winyard P. Oxidative stress in rheumatoid arthritis. In: Studies on Arthritis and Joint Disorders. Springer Science+Business Media; 2013. p. 145\u201367 [Alcaraz MJ (Series Editor): Oxidative Stress in Applied Basic Research and Clinical Practice].","DOI":"10.1007\/978-1-4614-6166-1_8"},{"key":"259_CR363","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3109\/10715762.2012.727991","volume":"46","author":"S Kundu","year":"2012","unstructured":"Kundu S, Ghosh P, Datta S, Ghosh A, Chattopadhyay S, Chatterjee M. Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis. Free Radic Res. 2012;46:1482\u20139.","journal-title":"Free Radic Res"},{"key":"259_CR364","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1756-185X.2011.01630.x","volume":"14","author":"S Hassan","year":"2011","unstructured":"Hassan S, Gheita T, Kenawy S, Fahim A, El-Sorougy I, Abdou M. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis. 2011;14:325\u201331.","journal-title":"Int J Rheum Dis"},{"key":"259_CR365","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0167-5699(99)01552-2","volume":"21","author":"P Tak","year":"2000","unstructured":"Tak P, Zvaifler N, Green D, Firestein G. Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today. 2000;21:78\u201382.","journal-title":"Immunol Today"},{"key":"259_CR366","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1186\/ar1752","volume":"7","author":"T Da Sylva","year":"2005","unstructured":"Da Sylva T, Connor A, Mburu Y, Keystone E, Wu G. Somatic mutations in the mitochondria of rheumatoid arthritis synoviocytes. Arthritis Res Ther. 2005;7:844\u201351.","journal-title":"Arthritis Res Ther"},{"key":"259_CR367","doi-asserted-by":"crossref","first-page":"A56","DOI":"10.1136\/ard.2010.129643t","volume":"69","author":"M Valc\u00e1rcel-Ares","year":"2010","unstructured":"Valc\u00e1rcel-Ares M, Vaamonde-Garcia C, Riveiro-Naveira R, Lema B, Blanco F, Lopez-Armada M. A novel role for mitochondrial dysfunction in the inflammatory response of rheumatoid arthritis [abstract]. Ann Rheum Dis. 2010;69:A56.","journal-title":"Ann Rheum Dis"},{"key":"259_CR368","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2474-14-235","volume":"14","author":"B Cillero-Pastor","year":"2013","unstructured":"Cillero-Pastor B, Rego-Perez I, Oreiro N, Fernandez-Lopez C, Blanco F. Mitochondrial respiratory chain dysfunction modulates metalloproteases-1,-3 and-13 in human normal chondrocytes in culture. BMC Musculoskelet Disord. 2013;14:1\u201310.","journal-title":"BMC Musculoskelet Disord"},{"key":"259_CR369","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.33326","volume":"64","author":"K Wartolowska","year":"2012","unstructured":"Wartolowska K, Hough M, Jenkinson M, Andersson J, Wordsworth B, Tracey I. Structural changes of the brain in rheumatoid arthritis. Arthritis Rheum. 2012;64:371\u20139.","journal-title":"Arthritis Rheum"},{"key":"259_CR370","first-page":"767","volume":"16","author":"SI Bekkelund","year":"1995","unstructured":"Bekkelund SI, Pierre-Jerome C, Husby G, Mellgren SI. Quantitative cerebral MR in rheumatoid arthritis. AJNR Am J Neuroradiol. 1995;16:767\u201372.","journal-title":"AJNR Am J Neuroradiol"},{"key":"259_CR371","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jcp.56.7.481","volume":"56","author":"CC Mok","year":"2003","unstructured":"Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56:481\u201390.","journal-title":"J Clin Pathol"},{"key":"259_CR372","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/1759720X10381431","volume":"2","author":"M Voulgarelis","year":"2010","unstructured":"Voulgarelis M, Tzioufas AG. Current aspects of pathogenesis in Sj\u00f6gren\u2019s syndrome. Ther Adv Musculoskelet Dis. 2010;2:325\u201334.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"259_CR373","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1177\/1352458514530021","volume":"20","author":"H Westerlind","year":"2014","unstructured":"Westerlind H, Bostr\u00f6m I, Stawiarz L, Landtblom AM, Almqvist C, Hillert J. New data identify an increasing sex ratio of multiple sclerosis in Sweden. Mult Scler. 2014;20:1578\u201383.","journal-title":"Mult Scler"},{"key":"259_CR374","first-page":"167","volume":"12","author":"I Bakken","year":"2014","unstructured":"Bakken I, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Trogstad L, et al. Two age peaks in the incidence of chronic fatigue syndrome\/myalgic encephalomyelitis: a population-based registry study from Norway 2008-2012. BMC Med. 2014;12:167.","journal-title":"BMC Med"},{"key":"259_CR375","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1192\/bjp.177.6.486","volume":"177","author":"M Piccinelli","year":"2000","unstructured":"Piccinelli M, Wilkinson G. Gender differences in depression. Critical review Br J Psychiatry. 2000;177:486\u201392.","journal-title":"Critical review. Br J Psychiatry"},{"key":"259_CR376","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jocn.2013.12.016","volume":"21","author":"M Lubomski","year":"2014","unstructured":"Lubomski M, Louise Rushworth R, Lee W, Bertram KL, Williams DR. Sex differences in Parkinson\u2019s disease. J Clin Neurosci. 2014;21:1503\u20136.","journal-title":"J Clin Neurosci"},{"key":"259_CR377","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-010-8242-y","volume":"42","author":"M Benkler","year":"2012","unstructured":"Benkler M, Agmon-Levin N, Hassin-Baer S, Cohen OS, Ortega-Hernandez OD, Levy A, et al. Immunology, autoimmunity, and autoantibodies in Parkinson\u2019s disease. Clin Rev Allergy Immunol. 2012;42:164\u201371.","journal-title":"Clin Rev Allergy Immunol"},{"key":"259_CR378","doi-asserted-by":"crossref","first-page":"A479","DOI":"10.1016\/j.autrev.2011.11.022","volume":"11","author":"S Oertelt-Prigione","year":"2012","unstructured":"Oertelt-Prigione S. The influence of sex and gender on the immune response. Autoimmun Rev. 2012;11:A479\u201385.","journal-title":"Autoimmun Rev"},{"key":"259_CR379","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2174\/156802611796117630","volume":"11","author":"S Munoz-Cruz","year":"2011","unstructured":"Munoz-Cruz S, Togno-Pierce C, Morales-Montor J. Non-reproductive effects of sex steroids: their immunoregulatory role. Curr Top Med Chem. 2011;11:1714\u201327.","journal-title":"Curr Top Med Chem"},{"key":"259_CR380","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1742-4933-9-24","volume":"9","author":"A Berghella","year":"2012","unstructured":"Berghella A, Contasta I, Del Beato T, Pellegrini P. The discovery of how gender influences age immunological mechanisms in health and disease, and the identification of ageing gender-specific biomarkers, could lead to specifically tailored treatment and ultimately improve therapeutic success rates. Immun Ageing. 2012;9:24.","journal-title":"Immun Ageing"},{"key":"259_CR381","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1742-2094-8-82","volume":"8","author":"M S\u00e1rv\u00e1ri","year":"2011","unstructured":"S\u00e1rv\u00e1ri M, Hrabovszky E, Kall\u00f3 I, Solymosi N, T\u00f3th K, Lik\u00f3 I, et al. Estrogens regulate neuroinflammatory genes via estrogen receptors \u03b1 and \u03b2 in the frontal cortex of middle-aged female rats. J Neuroinflammation. 2011;8:82.","journal-title":"J Neuroinflammation"},{"key":"259_CR382","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1179\/030801811X13013181961518","volume":"36","author":"L Schiebinger","year":"2011","unstructured":"Schiebinger L, Schraudner M. Interdisciplinary approaches to achieving gendered innovations in science, medicine, and engineering. Interdisc Science Rev. 2011;36:154\u201367.","journal-title":"Interdisc Science Rev"},{"key":"259_CR383","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0264-410X(02)00172-X","volume":"20","author":"P Pittman","year":"2002","unstructured":"Pittman P. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine. 2002;20:S48\u201350.","journal-title":"Vaccine"},{"key":"259_CR384","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/gene.2008.80","volume":"10","author":"D Reif","year":"2008","unstructured":"Reif D, Motsinger-Reif A, McKinney B, Rock M, Crowe J, Moore J. Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination. Genes Immun. 2008;10:112\u20139.","journal-title":"Genes Immun"},{"key":"259_CR385","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/eci.13.2","volume":"9","author":"O Vera-Lastra","year":"2013","unstructured":"Vera-Lastra O, Medina G, Cruz-Dominguez M, Jara L, Shoenfeld Y. Autoimmune\/inflammatory syndrome induced by adjuvants (Shoenfeld\u2019s syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol. 2013;9:361\u201373.","journal-title":"Expert Rev Clin Immunol"},{"key":"259_CR386","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.autrev.2008.07.026","volume":"8","author":"A Nancy","year":"2008","unstructured":"Nancy A, Shoenfeld Y. Chronic fatigue syndrome with autoantibodies\u2013the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev. 2008;8:52\u20135.","journal-title":"Autoimmun Rev"},{"key":"259_CR387","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.181.6.3755","volume":"181","author":"M Kool","year":"2008","unstructured":"Kool M, Petrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M, et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol. 2008;181:3755\u20139.","journal-title":"J Immunol"},{"key":"259_CR388","first-page":"427","volume":"28","author":"Z Yan","year":"2010","unstructured":"Yan Z, Zhang Q, Xu L, Wu W, Ren W, Liu LH, et al. Involvement of Toll-like receptor in silica-induced tumor necrosis factor alpha release from human macrophage cell line. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2010;28:427\u20139 [in Chinese].","journal-title":"Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi"},{"key":"259_CR389","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1741-7015-11-101","volume":"11","author":"C Perricone","year":"2013","unstructured":"Perricone C, Agmon-Levin N, Shoenfeld Y. Novel pebbles in the mosaic of autoimmunity. BMC Med. 2013;11:101.","journal-title":"BMC Med"},{"key":"259_CR390","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","volume":"123","author":"M Pfreundschuh","year":"2013","unstructured":"Pfreundschuh M, Muller C, Zeynalova S, Kuhnt E, Wiesen M, Held G, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2013;123:640\u20136.","journal-title":"Blood"},{"key":"259_CR391","first-page":"1","volume":"83","author":"G Anderson","year":"2014","unstructured":"Anderson G. Gender differences in pharmacological response. Int Rev Neurobiol. 2014;83:1\u201310.","journal-title":"Int Rev Neurobiol"},{"key":"259_CR392","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1742-4933-10-42","volume":"10","author":"A Sivro","year":"2013","unstructured":"Sivro A, Lajoie J, Kimani J, Jaoko W, Plummer F, Fowke K, et al. Age and menopause affect the expression of specific cytokines\/chemokines in plasma and cervical lavage samples from female sex workers in Nairobi. Kenya Immun Ageing. 2013;10:42.","journal-title":"Kenya. Immun Ageing"},{"key":"259_CR393","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.seminhematol.2010.01.010","volume":"47","author":"R Stasi","year":"2010","unstructured":"Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol. 2010;47:170\u20139.","journal-title":"Semin Hematol"},{"key":"259_CR394","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","volume":"55","author":"M Tsuda","year":"2012","unstructured":"Tsuda M, Moritoki Y, Lian Z, Zhang W, Yoshida K, Wakabayashi K, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012;55:512\u201321.","journal-title":"Hepatology"},{"key":"259_CR395","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/art.30314","volume":"63","author":"F van de Veerdonk","year":"2011","unstructured":"van de Veerdonk F, Lauwerys B, Marijnissen R, Timmermans K, Di Padova F, Koenders MI, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011;63:1507\u201316.","journal-title":"Arthritis Rheum"},{"key":"259_CR396","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/s10165-009-0244-3","volume":"20","author":"A Yamamoto","year":"2009","unstructured":"Yamamoto A, Sato K, Miyoshi F, Shindo Y, Yoshida Y, Yokota K, et al. Analysis of cytokine production patterns of peripheral blood mononuclear cells from a rheumatoid arthritis patient successfully treated with rituximab. Mod Rheumatol. 2009;20:183\u20137.","journal-title":"Mod Rheumatol"},{"key":"259_CR397","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12035-014-8705-x","volume":"50","author":"G Morris","year":"2014","unstructured":"Morris G, Anderson G, Dean O, Berk M, Galecki P, Martin-Subero M, et al. The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol. 2014;50:1059\u201384.","journal-title":"Mol Neurobiol"},{"key":"259_CR398","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11926-013-0378-3","volume":"15","author":"CM Greco","year":"2013","unstructured":"Greco CM, Nakajima C, Manzi S. Updated review of complementary and alternative medicine treatments for systemic lupus erythematosus. Curr Rheumatol Rep. 2013;15:378.","journal-title":"Curr Rheumatol Rep"},{"key":"259_CR399","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10787-011-0111-7","volume":"20","author":"M Maes","year":"2012","unstructured":"Maes M, Fi\u0161ar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates\u2013Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012;20:127\u201350.","journal-title":"Inflammopharmacology"},{"key":"259_CR400","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1368-5031.2004.00073.x","volume":"58","author":"BK Puri","year":"2004","unstructured":"Puri BK, Holmes J, Hamilton G. Eicosapentaenoic acid-rich essential fatty acid supplementation in chronic fatigue syndrome associated with symptom remission and structural brain changes. Int J Clin Pract. 2004;58:297\u20139.","journal-title":"Int J Clin Pract"},{"key":"259_CR401","first-page":"1551","volume":"31","author":"EM Duffy","year":"2004","unstructured":"Duffy EM, Meenagh GK, McMillan SA, Strain JJ, Hannigan BM, Bell AL. The clinical effect of dietary supplementation with omega-3 fish oils and\/or copper in systemic lupus erythematosus. J Rheumatol. 2004;31:1551\u20136.","journal-title":"J Rheumatol"},{"key":"259_CR402","doi-asserted-by":"crossref","first-page":"349S","DOI":"10.1093\/ajcn\/71.1.349s","volume":"71","author":"JM Kremer","year":"2000","unstructured":"Kremer JM. n-3 fatty acid supplements in rheumatoid arthritis. Am J Clin Nutr. 2000;71:349S\u201351S.","journal-title":"Am J Clin Nutr"},{"key":"259_CR403","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jad.2014.06.001","volume":"167","author":"AL Lopresti","year":"2014","unstructured":"Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord. 2014;167:368\u201375.","journal-title":"J Affect Disord"},{"key":"259_CR404","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/ptr.4639","volume":"26","author":"B Chandran","year":"2012","unstructured":"Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. 2012;26:1719\u201325.","journal-title":"Phytother Res"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-014-0259-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-014-0259-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-014-0259-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-014-0259-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T07:16:47Z","timestamp":1747552607000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-014-0259-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,6]]},"references-count":404,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1186\/s12916-014-0259-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,6]]},"assertion":[{"value":"19 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"28"}}